INVACARE (IVCRQ) 10-Q 6 Nov 13 2013 Q3 Quarterly report Financial data

DEI_Document

DEI Document	9 Months Ended
	Sep. 30, 2013	Nov. 04, 2013	Nov. 04, 2013
		Common Class B (Authorized 12,000 shares; 1,085 and 1,086, issued and outstanding in 2013 and 2012, respectively - no par	Common Class A [Member]
Document Information [Line Items]	'	'	'
Entity Registrant Name	'INVACARE CORPORATION	'	'
Entity Central Index Key	'0000742112	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-Q	'	'
Document Period End Date	30-Sep-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'Q3	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	1,084,747	30,921,729

Consolidated_Statement_Of_Comp

Consolidated Statement Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$341,176	$361,518	$1,017,373	$1,077,767
Cost of Goods Sold	244,352	252,106	733,408	746,369
Gross Profit	96,824	109,412	283,965	331,398
Selling, general and administrative expense	98,719	103,281	306,042	306,755
Charge related to restructuring activities	1,884	1,175	6,998	3,742
Loss on debt extinguishment including debt finance charges and associated fees	0	0	0	312
Asset Impairment Charges	167	0	167	0
Interest expense	745	2,114	2,677	6,339
Interest income	-58	-166	-239	-610
Earnings before Income Taxes	-4,633	3,008	-31,680	14,860
Income Tax Expense (Benefit)	750	2,445	3,900	14,486
Income (Loss) from Continuing Operations Attributable to Parent	-5,383	563	-35,580	374
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax amounts of $227, $2,629; $237 and $5,264, respectively	307	2,301	3,321	8,746
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax amounts of $1,583 and $11,083	21,178	0	71,080	0
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	21,485	2,301	74,401	8,746
Net Earnings (loss)	16,102	2,864	38,821	9,120
Common Stock, Dividends, Per Share, Declared	$0.01	$0.01	$0.04	$0.04
Income (Loss) from Continuing Operations, Per Basic Share	($0.17)	$0.02	($1.12)	$0.01
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	$0.67	$0.07	$2.33	$0.27
Net Earnings (loss) per Share - Basic	$0.50	$0.09	$1.21	$0.28
Weighted Average Shares Outstanding - Basic	31,902	31,877	31,902	31,838
Income (Loss) from Continuing Operations, Per Diluted Share	($0.17)	$0.02	($1.12)	$0.01
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	$0.67	$0.07	$2.32	$0.27
Net Earnings (loss) per Share - Assuming Dilution	$0.50	$0.09	$1.20	$0.28
Weighted Average Shares Outstanding - Assuming Dilution	32,066	31,901	32,009	31,847
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'
Foreign currency translation adjustments	9,790	15,764	554	-24,288
Defined Benefit Plans	'	'	'	'
Amortization of prior service costs and unrecognized gains (losses)	359	38	895	136
Amounts arising during the year, primarily due to the addition of new participants	-154	0	-320	-168
Deferred tax adjustment resulting from defined benefit plan activity	-71	-13	-199	13
Valuation reserve (reversal) associated with defined benefit plan activity	69	13	193	-17
Current period unrealized gain (loss) on cash flow hedges	-104	-1,322	779	-276
Deferred tax benefit (loss) related to unrealized gain (loss) on cash flow hedges	-15	38	-57	-73
Other Comprehensive Income (Loss), Net of Tax	9,874	14,518	1,845	-24,673
Comprehensive Income	$25,976	$17,382	$40,666	($15,553)

Consolidated_Statement_Of_Comp1

Consolidated Statement Of Comprehensive Income (Parentheticals) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Discontinued Operation, Tax Effect of Discontinued Operation	$227	$2,629	$237	$5,264
Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation	$1,583	$0	$11,083	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$32,625	$38,791
Trade receivables, net	191,464	198,791
Installment receivables, net	1,560	2,188
Inventories, net	167,368	183,246
Other current assets	33,830	41,776
Assets Held-for-sale, Current	0	103,157
Total Current Assets	426,847	567,949
Other Assets	40,327	42,262
Other Intangibles	65,105	71,652
Property and Equipment, net	108,391	118,231
Goodwill	450,727	462,200
Total Assets	1,091,397	1,262,294
Current Liabilities	'	'
Accounts payable	117,684	133,048
Accrued expenses	130,479	135,189
Accrued income taxes	7,201	2,713
Short-term debt and current maturities of long-term obligations	1,294	5,427
Liabilities of Assets Held-for-sale	0	23,358
Total Current Liabilities	256,658	299,735
Long-Term Debt	54,775	229,375
Other Long-Term Obligations	114,773	112,195
Shareholders' Equity	'	'
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	232,881	228,187
Retained earnings	402,181	364,546
Accumulated other comprehensive earnings	114,588	112,743
Treasury shares	-93,262	-93,262
Total Shareholders' Equity	665,191	620,989
Total Liabilities and Shareholders' Equity	1,091,397	1,262,294
Common Class A [Member]	'	'
Common Stock, Shares, Issued	34,053	33,952
Common Shares (Authorized 100,000 shares; 34,053 and 33,952 issued in 2013 and 2012, respectively) - no par	'	'
Shareholders' Equity	'	'
Common Shares	8,531	8,503
Common Class B (Authorized 12,000 shares; 1,085 and 1,086, issued and outstanding in 2013 and 2012, respectively - no par	'	'
Common Stock, Shares, Issued	1,085	1,086
Shareholders' Equity	'	'
Common Shares	$272	$272

Balance_Sheet_Parentheticals

Balance Sheet Parentheticals (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	3,135	3,135
Common Class A [Member]	'	'
Common Stock, Shares Authorized	100,000	100,000
Common Stock, Shares, Issued	34,053	33,952
Common Stock, Par or Stated Value Per Share	0	0
Common Class B [Member]	'	'
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	1,085	1,086
Common Stock, Par or Stated Value Per Share	0	0

Consolidated_Statement_Of_Cash

Consolidated Statement Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities	'	'
Net Earnings (loss)	$38,821	$9,120
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	-82,163	0
Depreciation and amortization	28,236	29,065
Provision for losses on trade and installment receivables	3,160	4,252
(Benefit) provision for deferred income taxes	2,698	628
Provision for other deferred liabilities	140	821
Provision for stock-based compensation	4,721	5,198
Loss on disposals of property and equipment	565	108
Loss on debt extinguishment including debt finance charges and associated fees	0	312
Amortization of convertible debt discount	468	430
Changes in operating assets and liabilities:	'	'
Trade receivables	3,049	-8,149
Installment sales contracts, net	-633	4,353
Inventories	10,599	-30,936
Other current assets	7,539	-90
Accounts payable	-16,848	-329
Accrued expenses	-390	251
Other long-term liabilities	-1,374	11,788
Net Cash Provided (Used) by Operating Activities	-1,245	26,822
Investing Activities	'	'
Purchases of property and equipment	-11,086	-14,775
Proceeds from sale of property and equipment	856	97
Proceeds from Divestiture of Business, net	187,552	0
(Increase) Decrease in other long-term assets	949	409
Other	-147	-219
Net Cash Used for Investing Activities	178,124	-14,488
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	250,124	255,703
Payments on revolving lines of credit and long-term borrowings	-432,185	-266,721
Payment of Financing Costs	0	-1
Payment of dividends	-1,187	-1,183
Net Cash Provided (Used) by Financing Activities	-183,248	-12,202
Effect of exchange rate changes on cash	203	226
Increase (decrease) in cash and cash equivalents	-6,166	358
Cash and cash equivalents at beginning of year	38,791	34,924
Cash and cash equivalents at end of year	$32,625	$35,282

Accounting_Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company’s distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets.
	Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of September 30, 2013, the results of its operations for the three and nine months ended September 30, 2013 and changes in its cash flow for the nine months ended September 30, 2013 and 2012, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using an August 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated.  The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.
	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
	Stock-Based Compensation Plans: The company accounts for share-based compensation under the provisions of Compensation-Stock Compensation, ASC 718. The company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted. The company continues to use a Black-Scholes valuation model.
	Stock options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods. The amounts of stock-based compensation expense recognized were as follows (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	2,147	$	2,208	$	4,721	$	5,198
	The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan and the 2013 Equity Compensation Plan. Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the company's Business Segment Note to the Consolidated Financial Statements.
	Recent Accounting Pronouncements: In February, 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02 or the ASU). ASU 2013-02 requires companies to report, in one place, changes in and reclassifications out of accumulated other comprehensive income (OCI). The ASU does not change what is required to be reported in OCI. The company adopted ASU 2013-02 in the first quarter of 2013 with no impact on the company's Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows. See Accumulated Other Comprehensive Income (Loss) in the Notes to these Consolidated Financial Statements.
	In February 2013, the FASB issued ASU No. 2013-04, Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. This update requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, as the sum of a) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and b) any additional amount the reporting entity expects to pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The requirements of ASU No. 2013-04 are effective on a retrospective basis for interim and annual periods beginning after December 15, 2013. The company is in the process of determining the effects, if any, that the adoption of ASU No. 2013-04 will have on the company’s financial position, results of operations or cash flows.
	In December, 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, and in January, 2013, issued ASU 2013-01, Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (ASU 2013-01). ASU 2013-01 is intended to help investors and other financial statement users to better assess the effect or potential effect of offsetting arrangements on an entity's financial position and requires companies to disclose both gross and net information about both instruments and transactions eligible for offset in the financial position; and to disclose instruments and transactions subject to an agreement similar to a master netting agreement. The company adopted ASU 2013-01 in the first quarter of 2013 with no impact on the company's Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows. See Derivatives in the Notes to these Consolidated Financial Statements. See Accumulated Other Comprehensive Income (Loss) in the Notes to these Consolidated Financial Statements.

Discontinued_Operations_Notes

Discontinued Operations (Notes)	9 Months Ended
	Sep. 30, 2013
Discontinued Operations [Abstract]	'
Discontinuted Operations	'
	Discontinued Operations
	On December 21, 2012, as part of the company's globalization strategy, and to allow it to focus on its core equipment product lines, the company entered into an agreement to sell Invacare Supply Group (ISG) and accordingly the company determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met. Accordingly, the assets and liabilities of ISG (long-lived asset disposal group) are shown at their carrying amounts, which are lower than the fair values less cost to sale as of December 31, 2012.
	On January 18, 2013, the company completed the sale of the ISG medical supplies business for a purchase price of $150,800,000 in cash, which remains subject to final post-closing adjustments. ISG had been operated on a stand-alone basis and reported as a reportable segment of the company. The company recorded a gain of $59,402,000 pre-tax in the first quarter of 2013 which represents the excess of the net sales price over the book value of the assets and liabilities of ISG. The sale of this business is dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the first quarter of 2013. The company recorded expenses related to the sale of $5,350,000, of which $3,392,000 were paid as of September 30, 2013. The gain recorded by the company reflects the company's estimated final purchase adjustments.
	The assets and liabilities of ISG that were sold are shown as held for sale in the company's Consolidated Balance Sheets and are comprised of the following (in thousands):
		December 31,
		2012
	Trade receivables, net	$	44,196
	Inventories, net	25,165
	Other current assets	9,355
	Property and Equipment, net	1,368
	Goodwill	23,073
	Assets held for sale - current	$	103,157
	Accounts payable	$	17,692
	Accrued expenses	4,602
	Accrued income taxes	1,064
	Liabilities held for sale - current	$	23,358
	The net sales of the discontinued operation were $0 and $18,498,000 for the three and nine months ended September 30, 2013 and $85,763,000 and $246,433,000 for the three and nine months ended September 30, 2012, respectively. Earnings before income taxes for the discontinued operation were $0 and $402,000 for the three and nine months ended September 30, 2013 and $3,894,000 and $10,703,000 for the three and nine months ended September 30, 2012, respectively.
	The company will continue to sell products to the acquirer of ISG and provide certain transitional services to the acquirer over a period of less than one year from the date of sale. The net cash flows expected to be paid and received related to such product sales and transitional services are not expected to be significant.
	On August 6, 2013, the company sold Champion Manufacturing, Inc. (Champion), its domestic medical recliner business for dialysis clinics, to Champion Equity Holdings, LLC for $45,000,000 in cash, which is subject to final post-closing adjustments. Champion had been operated on a stand-alone basis and reported as part of the IPG segment of the company. The company recorded a gain of $22,761,000 pre-tax in the third quarter of 2013, which represents the excess of the net sales price over the book value of the assets and liabilities of Champion. The sale of this business is dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2013. The company recorded expenses related to the sale of $2,130,000, of which $1,367,000 were paid as of September 30, 2013. The gain recorded by the company reflects the company's estimated final purchase adjustments.
	The assets and liabilities of Champion were the following as of the date of the sale, August 6, 2013, and as of December 31, 2012 (in thousands):
		August 6,		December 31,
		2013		2012
	Trade receivables, net	$	3,030	$	2,375
	Inventories, net	1,689		1,617
	Other current assets	92		21
	Property and Equipment, net	309		237
	Goodwill	16,277		16,277
	Assets sold	$	21,397	$	20,527
	Accounts payable	$	936	$	475
	Accrued expenses	352		318
	Accrued income taxes	—		200
	Liabilities sold	$	1,288	$	993
	The net sales of the discontinued operation were $2,643,000 and $15,857,000 for the three and nine months ended September 30, 2013 and $5,700,000 and $17,271,000 for the three and nine months ended September 30, 2012, respectively. Earnings before income taxes for the discontinued operation were $484,000 and $3,156,000 for the three and nine months ended September 30, 2013 and $1,037,000 and $3,307,000 for the three and nine months ended September 30, 2012, respectively. Results for Champion include an interest expense allocation from continuing operations to discontinued operations of $78,000 and $449,000 for the three and nine months ended September 30, 2013 and $198,000 and $594,000 for the three and nine months ended September 30, 2012, respectively, as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the company's average interest rates for the periods presented.
	In addition, in accordance with ASC 350, when a portion of a reporting entity that constitutes a business is disposed of, goodwill associated with that business should be included in the carrying amount of the net assets of the business sold in determining the gain or loss on the disposal. As such, the company allocated additional goodwill of $16,205,000 to Champion from the continuing operations of the IPG segment based on the relative fair value of Champion as compared to the remaining IPG reporting unit.
	The company will continue to purchase an immaterial amount of products from the acquirer of Champion until the company transitions manufacturing of the product, which is expected to occur before the end of the year.
	The company recorded an incremental intra-period tax allocation expense to discontinued operations in the quarter representing the cumulative intra-period allocation expense to discontinued operations based on the company's current estimate of the projected domestic taxable loss related to continuing operations for 2013. The amount recorded through September 30, 2013 is less than the federal statutory rate as the expected taxable loss in continuing operations is less than the taxable gain from discontinued operations.
	The company has classified ISG and Champion as discontinued operations for all periods presented.

Receivables

Receivables	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Receivables	'
	Receivables
	Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($20,836,000 at September 30, 2013 and $22,213,000 at December 31, 2012) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the company's third party financing arrangement with De Lage Landen, Inc. ("DLL"), a third party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet.
	The company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, the company often provides financing directly for its Canadian customers for which DLL is not an option. The installment receivables recorded on the books of the company represent a single portfolio segment of finance receivables to the independent provider channel. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by 3 payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by the company because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for 12 months and historically have had a very low risk of default.
	The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. The company is closely monitoring the roll-out of the second round of NCB, which became effective in 91 additional metropolitan statistical areas on July 1, 2013. At this early stage of the program, it is difficult to characterize the impact from NCB on its domestic home medical equipment business, as there continues to be uncertainty as the industry realigns and adjusts itself to the small number of bid contracts awarded.
	For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000 which generally includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws.
	Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process of adjudication which typically approximates 18 months. Any write-offs are made after the legal process has been completed. The company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months.
	Installment receivables consist of the following (in thousands):
		September 30, 2013									December 31, 2012
		Current			Long-			Total			Current			Long-			Total
					Term									Term
	Installment receivables	$	3,554		$	2,394		$	5,948		$	4,982		$	1,506		$	6,488
	Less: Unearned interest	(70		)	—			(70		)	(71		)	—			(71		)
		3,484			2,394			5,878			4,911			1,506			6,417
	Allowance for doubtful accounts	(1,924		)	(1,718		)	(3,642		)	(2,723		)	(1,100		)	(3,823		)
		$	1,560		$	676		$	2,236		$	2,188		$	406		$	2,594
	Installment receivables purchased from DLL during the nine months ended September 30, 2013 increased the gross installment receivables balance by $2,415,000. No sales of installment receivables were made by the company during the quarter.
	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):
		Nine Months Ended June 30, 2013			Year Ended December 31, 2012
	Balance as of beginning of period	$	3,823		$	4,273
	Current period provision	943			458
	Direct write-offs charged against the allowance	(1,124		)	(908		)
	Balance as of end of period	$	3,642		$	3,823
	Installment receivables by class as of September 30, 2013 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	4,510		$	4,510		$	3,477		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,273			1,203			—			76
	Impaired Installment receivables with a related allowance recorded	165			165			165			—
	Total Canadian Installment Receivables	$	1,438		$	1,368		$	165		$	76
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,273			1,203			—			76
	Impaired Installment receivables with a related allowance recorded	4,675			4,675			3,642			—
	Total Installment Receivables	$	5,948		$	5,878		$	3,642		$	76
	Installment receivables by class as of December 31, 2012 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	4,508		$	4,508		$	3,365		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,522			1,451			—			120
	Impaired Installment receivables with a related allowance recorded	458			458			458			—
	Total Canadian Installment Receivables	$	1,980		$	1,909		$	458		$	120
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,522			1,451			—			120
	Impaired Installment receivables with a related allowance recorded	4,966			4,966			3,823			—
	Total Installment Receivables	$	6,488		$	6,417		$	3,823		$	120
	Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of September 30, 2013, the company had no U.S. installment receivables past due of 90 days or more for which the company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. However, while the full balance may be deemed to be impaired, the company has historically collected a large percentage of the principal of its U.S. installment receivables.
	The company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of September 30, 2013 and December 31, 2012 for which the company is still accruing interest. The aging of the company’s installment receivables was as follows (in thousands):
		September 30, 2013									31-Dec-12
		Total			U.S.			Canada			Total			U.S.			Canada
	Current	$	1,218		$	—		$	1,218		$	1,467		$	—		$	1,467
	0-30 Days Past Due	9			—			9			43			—			43
	31-60 Days Past Due	6			—			6			2			—			2
	61-90 Days Past Due	—			—			—			—			—			—
	90+ Days Past Due	4,715			4,510			205			4,976			4,508			468
	$	5,948		$	4,510		$	1,438		$	6,488		$	4,508		$	1,980

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory, Net [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		30-Sep-13		31-Dec-12
	Finished goods	$	90,422	$	94,675
	Raw materials	61,642		71,596
	Work in process	15,304		16,975
		$	167,368	$	183,246

Other_Current_Assets_Notes

Other Current Assets (Notes)	9 Months Ended
	Sep. 30, 2013
Other Current Assets [Abstract]	'
Other Assets Disclosure [Text Block]	'
	Other Current Assets
	Other current assets consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Value added tax receivables	$	15,004	$	18,002
	Recoverable income taxes	3,457		6,192
	Derivatives (foreign currency forward contracts)	1,311		1,062
	Prepaid insurance	300		2,241
	Prepaids and other current assets	13,758		14,279
		$	33,830	$	41,776

Other_LongTerm_Assets_Notes

Other Long-Term Assets (Notes)	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Investments and Other Noncurrent Assets [Text Block]	'
	Other Long-Term Assets
	Other long-term assets consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Cash surrender value of life insurance policies	$	35,772	$	36,375
	Deferred Financing Fees	1,356		2,728
	Investments	1,190		1,171
	Long-term installment receivables	676		406
	Other	1,333		1,582
		$	40,327	$	42,262

Property_And_Equipment

Property And Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property And Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		September 30, 2013			December 31, 2012
	Machinery and equipment	$	356,935		$	356,512
	Land, buildings and improvements	90,234			95,047
	Furniture and fixtures	12,998			13,397
	Leasehold improvements	14,886			14,975
		475,053			479,931
	Less allowance for depreciation	(366,662		)	(361,700		)
		$	108,391		$	118,231

Goodwill_And_Other_Intangibles

Goodwill And Other Intangibles	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Goodwill
	The goodwill decrease reflected on the balance sheet from December 31, 2012 to September 30, 2013 was due to the sale of Champion which decreased goodwill by $16,277,000, partially offset by an increase in goodwill due to foreign currency translation.

Other_Intangibles

Other Intangibles	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Other Intangibles
	All of the company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $31,299,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2012 to September 30, 2013 were the result of foreign currency translation, amortization and an intangible impairment write-down charge of $167,000 for a customer list in the NA/HME segment. The after-tax and pre-tax impairment amounts were the same for the impairment. The company's intangibles consist of the following (in thousands):
		September 30, 2013				December 31, 2012
		Historical		Accumulated		Historical		Accumulated
		Cost		Amortization		Cost		Amortization
	Customer Lists	$	91,344	$	61,888	$	93,572	$	58,447
	Trademarks	31,299		—		31,280		—
	License Agreements	1,428		1,428		3,212		3,212
	Developed Technology	9,712		6,098		9,650		5,588
	Patents	6,115		5,472		6,060		5,234
	Other	7,481		7,388		7,571		7,212
		$	147,379	$	82,274	$	151,345	$	79,693
	Amortization expense related to other intangibles was $6,937,000 in the first nine months of 2013 and is estimated to be $9,182,000 in 2013, $8,670,000 in 2014, $7,174,000 in 2015, $5,796,000 in 2016, $2,290,000 in 2017 and $2,290,000 in 2018. Amortized intangibles are being amortized on a straight-line basis for periods from 3 to 17 years with the majority of the intangibles being amortized over a life of between 10 and 13 years.

Current_Liabilities_Notes

Current Liabilities (Notes)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Current Liabilities Disclosure [Text Block]	'
	Current Liabilities
	Accrued expenses consist of accruals for the following (in thousands):
		September 30, 2013		December 31, 2012
	Salaries and wages	$	37,480	$	41,813
	Taxes other than income taxes, primarily Value Added Taxes	23,225		24,600
	Warranty cost	25,020		21,451
	Freight	7,806		7,853
	Professional	7,355		7,595
	Product liability, current portion	3,572		3,323
	Rebates	2,136		3,635
	Insurance	2,726		2,674
	Interest	921		1,268
	Derivative liabilities	771		1,373
	Severance	3,481		5,211
	Other items, principally trade accruals	15,986		14,393
		$	130,479	$	135,189
	Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in ASC 605-50, Customer Payments and Incentives.

Warrany_Costs

Warrany Costs	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities, Current [Abstract]	'
Current Liabilities	'
	Generally, the company's products are covered from the date of sale to the customer by warranties against defects in material and workmanship for various periods depending on the product. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. The increase in the liability for pre-existing warranties in 2013 is primarily the result of product recalls. The warranty accrual as of September 30, 2013 includes anticipated warranty expense related to the power wheelchair joystick recall of $3,800,000, provided for during the second quarter of 2013, which primarily impacted the Asia/Pacific segment. No change was made in the warranty accrual related to the power wheelchair joystick recall during the quarter ended September 30, 2013.
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):
	Balance as of January 1, 2013	$	21,451
	Warranties provided during the period	7,843
	Settlements made during the period	(8,741		)
	Changes in liability for pre-existing warranties during the period, including expirations	4,467
	Balance as of September 30, 2013	$	25,020

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	Debt consists of the following (in thousands):
		September 30, 2013			December 31, 2012
	Senior secured revolving credit facility, due in October 2015	$	38,968		$	217,494
	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,476			10,009
	Other notes and lease obligations	6,625			7,299
		56,069			234,802
	Less current maturities of long-term debt	(1,294		)	(5,427		)
		$	54,775		$	229,375
	The reduction in debt during the year was principally the result of utilizing the proceeds from the sale of the discontinued operations of ISG and Champion to reduce borrowing under the company's revolving credit agreement. On May 30, 2013, the company entered into a Fourth Amendment ("the Amendment") to its Credit Agreement (the “Credit Agreement”). Pursuant to the Amendment, the Credit Agreement was amended to: (i) decrease the aggregate principal amount of the revolving credit facility to $250,000,000 from $400,000,000, and limit the company's borrowings under the revolving credit facility to an amount not to exceed $200,000,000 aggregate principal amount through December 31, 2013; (ii) increase the maximum leverage ratio (consolidated funded indebtedness to consolidated EBITDA, each as defined in the Credit Agreement, as amended) to 4.00 to 1.00 from 3.50 to 1.00 until January 1, 2014, when the maximum leverage ratio will revert back to 3.50 to 1.00; (iii) decrease the minimum interest coverage ratio (consolidated EBITDA to consolidated interest charges, each as defined in the Credit Agreement, as amended) to 3.00 to 1.00 from 3.50 to 1.00 until January 1, 2014, when the minimum interest coverage ratio will revert back to 3.50 to 1.00; (iv) in calculating consolidated EBITDA for purposes of determining the ratios, provide for the add back to consolidated EBITDA of up to an additional $15,000,000 for future one-time cash restructuring charges and (v) provide for an increase of (A) 25 basis points in the margin applicable to determining the interest rate on borrowings under the revolving credit facility and letter of credit fees and (B) 10 basis points in the commitment fee, all during periods when the leverage ratio exceeds 3.50 to 1.00. Compliance with the ratios is tested at the end of the quarter in accordance with the credit agreement. As a result of the amendment, the company incurred $436,000 in fees in the second quarter of 2013 which were capitalized and are being amortized through October, 2015. In addition, as a result of reducing the capacity of the facility from $400,000,000 to $250,000,000, the company wrote-off $1,216,000 in fees previously capitalized in the second quarter of 2013, which is reflected in the expense of the North America / HME segment.
	In 2007, the company issued $135,000,000 principal amount of Convertible Senior Subordinated Debentures due 2027. The debentures are unsecured senior subordinated obligations of the company guaranteed by substantially all of the company’s domestic subsidiaries, pay interest at 4.125% per annum on each February 1 and August 1, and are convertible upon satisfaction of certain conditions into cash, common shares of the company, or a combination of cash and common shares of the company, subject to certain conditions. The debentures allow the company to satisfy the conversion using any combination of cash or stock, and at the company’s discretion. The company intends to satisfy the accreted value of the debentures using cash. Assuming adequate cash on hand at the time of conversion, the company also intends to satisfy the conversion spread using cash, as opposed to stock.
	The company may from time to time seek to retire or purchase its 4.125% Convertible Senior Subordinated Debentures due 2027, in open market purchases, privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material.
	The liability components of the company’s convertible debt consist of the following (in thousands):
		September 30, 2013			December 31, 2012
	Principal amount of liability component	$	13,350		$	13,350
	Unamortized discount	(2,874		)	(3,341		)
	Net carrying amount of liability component	$	10,476		$	10,009
	The company is a party to an interest rate swap agreement to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, an interest rate swap agreement for a notional amount of $12,000,000 through April 2014 was entered into that fixes the LIBOR component of the interest rate on that portion of the revolving credit facility debt at a rate of 0.54% for an effective aggregate rate 3.04%. As of September 30, 2013, the weighted average floating interest rate on revolving credit borrowings was 2.45% compared to 2.21% as of December 31, 2012.

Shareholders_Equity_Transactio

Shareholders' Equity Transactions	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity Transactions	'
	Shareholders’ Equity Transactions
	On May 16, 2013 shareholders approved the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”), which was adopted on March 27, 2013 by the company's Board of Directors (the “Board”). The Board adopted the 2013 Plan because the ten-year term of the company's prior equity plan, the Invacare Corporation Amended and Restated 2003 Performance Plan (the “2003 Plan”), expired on May 21, 2013. No new awards will be granted under the 2003 Plan following its expiration, but awards granted prior to its expiration will remain in effect under their original terms.
	The 2013 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or SARs will count against the number of total shares available under the 2013 Plan as one share; and each common share underlying any award other than a stock option or a stock appreciation rights (“SAR”) will count against the number of total shares available under the 2013 Plan as two shares. Any common shares that are added back to the 2013 Plan as the result of the cancellation or forfeiture of an award granted under the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2013 Plan. Each common share that is added back to the 2013 Plan due to a cancellation or forfeiture of an award granted under the 2003 Plan will be added back as one common share.
	The Compensation and Management Development Committee of the Board (the “Committee”), in its discretion, may grant an award under the 2013 Plan to any director or employee of the company or an affiliate. The 2013 Plan initially allows the Committee to grant up to 4,460,337 Common Shares in connection with the following types of awards with respect to shares of the company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock, and performance shares. The Committee also may grant performance units that are payable in cash. The Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards.
	During the nine months ended September 30, 2013, the Committee granted 756,700 non-qualified stock options, each having a term of ten years and generally granted at the fair market value of the company’s Common Shares on the date of grant. In addition, restricted stock awards for 114,700 shares were granted without cost to the recipients which vest ratably over the four years after the award date. Compensation expense of $1,568,000 was recognized during the nine months ended September 30, 2013 related to restricted stock awards and there were outstanding restricted stock awards totaling 362,323 shares that were not vested.
	As of September 30, 2013, there was $13,264,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the plan, which is related to non-vested options and shares, and includes $4,169,000 related to restricted stock awards. The company expects the compensation expense to be recognized over a weighted-average period of approximately two years.
	The following table summarizes information about stock option activity for the nine months ended September 30, 2013:
		September 30, 2013				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2013	4,664,634				$	26.21
	Granted	756,700				14.47
	Exercised	—				—
	Canceled	(792,584		)		28.74
	Options outstanding at September 30, 2013	4,628,750				$	23.86
	Options exercise price range at September 30, 2013	$ 12.42 to
		$	47.8
	Options exercisable at September 30, 2013	3,070,364
	Options available for grant at September 30, 2013*	4,460,337
	________________________
	*	Options available for grant as of September 30, 2013 reduced by net restricted stock award activity of 793,351.
	The following table summarizes information about stock options outstanding at September 30, 2013:
		Options Outstanding							Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average		Number	Weighted Average
		Outstanding			Remaining		Exercise Price		Exercisable	Exercise Price
		At 9/30/13			Contractual Life (Years)				At 9/30/13
	$ 12.42 – $15.00	1,354,435			9.2		$	13.95	166,045	$	13.38
	$ 15.01 – $25.00	1,613,291			5.6		22.51		1,364,559	22.21
	$ 25.01 – $35.00	950,109			5.7		25.81		828,846	25.85
	$ 35.01 – $47.80	710,915			1.4		43.21		710,914	43.21
	Total	4,628,750			6		$	23.86	3,070,364	$	27.57
	When stock options are awarded, they generally become exercisable over a four-year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the company's historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the company has no current intention of changing its dividend policy.
	The 2013 Plan provides that shares granted come from the company's authorized but unissued Common Shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	Accumulated Other Comprehensive Income (Loss) by Component
	Changes in accumulated other comprehensive income (Loss) ("OCI") during the quarter ended September 30, 2013 were as follows (in thousands):
		Foreign Currency		Long-Term Notes		Defined Benefit Plans		Derivatives		Total
	June 30, 2013	117,817		(6,743	)	(6,419	)	59		104,714
	OCI before reclassifications	17,852		(8,062	)	265		(197	)	9,858
	Amount reclassified from accumulated OCI	—		—		(62	)	78		16
	Net current-period OCI	17,852		(8,062	)	203		(119	)	9,874
	30-Sep-13	135,669		(14,805	)	(6,216	)	(60	)	114,588
	Changes in OCI during the nine months ended September 30, 2013 were as follows (in thousands):
		Foreign Currency		Long-Term Notes		Defined Benefit Plans		Derivatives		Total
	December 31, 2012	117,465		2,845		(6,785	)	(782	)	112,743
	OCI before reclassifications	18,204		(17,650	)	750		650		1,954
	Amount reclassified from accumulated OCI	—		—		(181	)	72		(109	)
	Net current-period OCI	18,204		(17,650	)	569		722		1,845
	30-Sep-13	135,669		(14,805	)	(6,216	)	(60	)	114,588
	Reclassifications out of accumulated OCI for the three and nine months ended September 30, 2013 were as follows (in thousands):
		Amount reclassified from OCI				Affected line item in the Statement of Comprehensive Income (Loss)
		Three Months Ended September 30, 2013		Nine Months Ended September 30, 2013
	Defined Benefit Plans
	Service and interest costs	(64	)	(187	)	Selling, General and Administrative
	Tax	2		6		Income Taxes
	Total after tax	(62	)	(181	)
	Derivatives
	Foreign currency forward contracts hedging sales	(54	)	(496	)	Net Sales
	Foreign currency forward contracts hedging purchases	128		453		Cost of Products Sold
	Interest rate swaps	13		139		Interest Expense
	Total before tax	87		96
	Tax	(9	)	(24	)	Income Taxes
	Total after tax	78		72

Charges_Related_To_Restructuri

Charges Related To Restructuring Activities	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Charges Related To Restructuring Activities	'
	Charges Related to Restructuring Activities
	Historically, the company's restructuring charges were necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company as a result of outsourcing by competitors to lower cost locations. In addition, restructuring actions principally in the North America/HME segment have been precipitated by the negative impact on the business related to the FDA consent decree which has resulted in a sales decline in custom power wheelchairs, which is one of the company's higher margin product lines. While the company's restructuring efforts have been executed on a timely basis resulting in operating cost savings, the savings have been more than offset by continued margin decline, principally as a result of volume declines, unfavorable product mix, and higher regulatory and compliance costs related to quality system improvements. The company expects any near-term cost savings from restructuring will be offset by higher regulatory and compliance costs related to quality system improvements at least until the company has completed its quality systems remediation efforts.
	The company's restructuring commenced in the second quarter of 2011 with the company's decision to close the Hong, Denmark assembly facility as part of the company's ongoing globalization initiative to reduce complexity in the company's supply chain which is intended to reduce expenses to help offset pricing pressures. In the third quarter of 2011, the company continued to execute on the closure of the Hong, Denmark assembly facility and initiated the closure of a smaller facility in the U.S. Charges for the quarter ended December 31, 2011 were primarily incurred at the company's corporate headquarters for severance, with additional costs incurred as a result of the closure of the Hong, Denmark facility. The facility closures were completed in 2012 in addition to the elimination of various positions principally in the North America/Home Medical Equipment (HME) and Asia/Pacific segments.
	Charges for the year ended December 31, 2011 totaled $10,534,000 including charges for severance ($8,352,000), contract exit costs primarily related to the closure of the Hong, Denmark assembly facility ($1,788,000) and inventory write-offs ($277,000) recorded in cost of products sold and other miscellaneous costs ($117,000). The majority of the 2011 North America/HME charges were incurred for severance, primarily at the corporate headquarters as the result of the elimination of various positions principally in sales and administration in Elyria, Ohio. These eliminations were permanent reductions in workforce which primarily resulted in reduced selling, general and administrative expenses. In Europe, the charges were the result of the closure of the company's Hong, Denmark facility. The assembly activities were transferred to other company facilities or outsourced to third parties. This closure enabled the company to reduce fixed operating costs related to the facility and reduce headcount with the transfer of a portion of the production to other company facilities. The 2011 charges have now been paid out and were funded with operating cash flows.
	Charges for the year ended December 31, 2012 totaled $11,395,000 including charges for severance ($6,775,000), lease termination costs ($1,725,000), building and asset write-downs, primarily related to the closure of the Hong, Denmark assembly facility, other miscellaneous charges, primarily building and asset write-downs, in Europe and Asia/Pacific ($2,404,000) and inventory write-offs ($491,000) in Asia/Pacific recorded in cost of products sold. Severance charges were primarily incurred in the North America/HME segment ($4,242,000), Asia/Pacific segment ($1,681,000) and Europe segment ($817,000). The charges were incurred as a result of the elimination of various positions as part of the company's globalization initiatives. In addition, a portion of the North America/HME segment severance was related to positions eliminated, principally in sales and marketing as well as manufacturing, at the company's Taylor Street facility as a result of the FDA consent decree. The savings from these charges are reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. In Europe, positions were eliminated as a result of finalizing the exit from the manufacturing facility in Denmark and an elimination of a senior management position in Switzerland. In Asia/Pacific, the company's management approved in the fourth quarter of 2012 a plan to restructure the company's operations in this segment. In Australia, the company consolidated offices / warehouses, decreased staffing and exited various activities while returning to a focus on distribution. At the company's subsidiary, which produces microprocessor controllers, the company decided to cease the contract manufacturing business for companies outside of the healthcare industry. Payments for the year ended December 31, 2012 were $9,381,000 and were funded with operating cash flows. The majority of the 2012 charges are expected to be paid out during 2013.
	Restructuring continued during 2013 resulting in restructuring charges of $6,998,000 in the first nine months of 2013 principally for severance in NA/HME and Asia/Pacific and to a lesser extent Europe and IPG as a result of the permanent elimination of certain positions. Payments for the nine months ended September 30, 2013 were $9,830,000 and were funded with the company's credit facility. The majority of the outstanding charge accruals at September 30, 2013 are expected to be paid out within the next twelve months.
	There have been no material changes in accrued balances related to the charges, either as a result of revisions in the plan or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. However, these savings have been more than offset by continued margin decline, principally as a result of volume declines, unfavorable product mix, and higher regulatory and compliance costs related to quality system improvements. To date, the company's liquidity has not been materially impacted by the company's restructuring charges.
	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2010 Balance
	Total	$	—		$	—		$	—		$	—		$	—
	Charges
	NA/HME	4,755			—			—			4			4,759
	IPG	123			—			—			—			123
	Europe	3,288			277			1,788			113			5,466
	Asia/Pacific	186			—			—			—			186
	Total	8,352			277			1,788			117			10,534
	Payments
	NA/HME	(1,663		)	—			—			(4		)	(1,667		)
	IPG	(52		)	—			—			—			(52		)
	Europe	(1,546		)	(277		)	(1,714		)	(113		)	(3,650		)
	Asia/Pacific	(186		)	—			—			—			(186		)
	Total	(3,447		)	(277		)	(1,714		)	(117		)	(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092			—			—			—			3,092
	IPG	71			—			—			—			71
	Europe	1,742			—			74			—			1,816
	Asia/Pacific	—			—			—			—			—
	Total	4,905			—			74			—			4,979
	Charges
	NA/HME	4,242			—			5			—			4,247
	IPG	35			—			—			—			35
	Europe	817			—			53			1,223			2,093
	Asia/Pacific	1,681			491			1,667			1,181			5,020
	Total	6,775			491			1,725			2,404			11,395
	Payments
	NA/HME	(3,587		)	—			(5		)	—			(3,592		)
	IPG	(106		)	—			—			—			(106		)
	Europe	(1,964		)	—			(127		)	(1,223		)	(3,314		)
	Asia/Pacific	(812		)	(340		)	(42		)	(1,175		)	(2,369		)
	Total	$	(6,469	)	$	(340	)	$	(174	)	$	(2,398	)	$	(9,381	)
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2012 Balance
	NA/HME	$	3,747		$	—		$	—		$	—		$	3,747
	IPG	—			—			—			—			—
	Europe	595			—			—			—			595
	Asia/Pacific	869			151			1,625			6			2,651
	Total	5,211			151			1,625			6			6,993
	Charges
	NA/HME	1,679			—			—			—			1,679
	IPG	189			—			—			—			189
	Europe	115			—			—			—			115
	Asia/Pacific	453			—			86			—			539
	Total	2,436			—			86			—			2,522
	Payments
	NA/HME	(2,005		)	—			—			—			(2,005		)
	IPG	(17		)	—			—			—			(17		)
	Europe	(461		)	—			—			—			(461		)
	Asia/Pacific	(618		)	(151		)	(766		)	(4		)	(1,539		)
	Total	(3,101		)	(151		)	(766		)	(4		)	(4,022		)
	March 31, 2013 Balance
NA/HME	3,421			—			—			—			3,421
IPG	172			—			—			—			172
Europe	249			—			—			—			249
Asia/Pacific	704			—			945			2			1,651
	4,546			—			945			2			5,493
Charges
NA/HME	1,948			—			—			—			1,948
IPG	13			—			—			—			13
Europe	65			—			—			—			65
Asia/Pacific	480			—			86			—			566
Total	2,506			—			86			—			2,592
Payments
NA/HME	(1,795		)	—			—			—			(1,795		)
IPG	(26		)	—			—			—			(26		)
Europe	(182		)	—			—			—			(182		)
Asia/Pacific	(129		)	—			(49		)	(2		)	(180		)
Total	(2,132		)	—			(49		)	(2		)	(2,183		)
June 30, 2013 Balance
NA/HME	3,574			—			—			—			3,574
IPG	159			—			—			—			159
Europe	132			—			—			—			132
Asia/Pacific	1,055			—			982			—			2,037
	$	4,920		$	—		$	982		$	—		$	5,902
	Severance			Product Line			Contract			Other			Total
				Discontinuance			Terminations
Charges
NA/HME	$	644		$	—		$	213		$	353		$	1,210
IPG	36			—			—			—			36
Europe	739			—			—			(198		)	541
Asia/Pacific	15			—			79			3			97
Total	1,434			—			292			158			1,884
Payments
NA/HME	(1,624		)	—			(85		)	(305		)	(2,014		)
IPG	(52		)	—			—			—			(52		)
Europe	(157		)	—			—			198			41
Asia/Pacific	(1,040		)	—			(557		)	(3		)	(1,600		)
Total	(2,873		)	—			(642		)	(110		)	(3,625		)
September 30, 2013 Balance
NA/HME	2,594			—			128			48			2,770
IPG	143			—			—			—			143
Europe	714			—			—			—			714
Asia/Pacific	30			—			504			—			534
	$	3,481		$	—		$	632		$	48		$	4,161

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The company had an effective tax rate of 16.2% and 12.3% on losses before tax from continuing operations for the three and nine month periods ended September 30, 2013, respectively, compared to an expected benefit at the U.S. statutory rate of 35%. The company's effective tax rate for the three and nine months ended September 30, 2013 was greater than the U.S. federal statutory rate, principally due to losses overseas without tax benefit due to valuation allowances, foreign dividends which reduced the domestic intra-period allocation benefit in continuing operations, and the recording of a discreet adjustment of $3,143,000 related to a federal domestic valuation allowance adjustment. The rate was benefited by taxes outside the United States, excluding countries with valuation allowances that are in losses in 2013, recorded at a lower effective rate than the U.S. statutory rate.
	The company had an effective tax rate of 81.3% and 97.5% on earnings before tax from continuing operations for the three and nine month period ended September 30, 2012, respectively, compared to an expected rate at the U.S. statutory rate of 35%. The company's effective tax rate for the three and nine months ended September 30, 2012 was greater than the U.S. federal statutory rate, principally due to a discrete foreign tax adjustment of $9,173,000 ($0.29 per share), recorded in the first nine months 2012, of which $3,178,000 was interest, related to prior year periods under audit, which is being contested by the company. This adjustment was partially offset by foreign earnings taxed at an effective rate lower than the U.S. statutory rate principally due to foreign taxes recognized at rates below the U.S. statutory rate.

Net_Earnings_Loss_Per_Common_S

Net Earnings (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Earnings (Loss) Per Common Share	'
	Net Earnings (Loss) Per Common Share
	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.
	(In thousands except per share data)	For the Three Months Ended September 30,					For the Nine Months Ended September 30,
		2013			2012		2013			2012
	Basic
	Average common shares outstanding	31,902			31,877		31,902			31,838
	Net earnings (loss) from continuing operations	$	(5,383	)	$	563	$	(35,580	)	$	374
	Net earnings from discontinued operations	$	21,485		$	2,301	$	74,401		$	8,746
	Net earnings	$	16,102		$	2,864	$	38,821		$	9,120
	Net earnings (loss) per common share from continuing operations	$	(0.17	)	$	0.02	$	(1.12	)	$	0.01
	Net earnings per common share from discontinued operations	$	0.67		$	0.07	$	2.33		$	0.27
	Net earnings per common share	$	0.5		$	0.09	$	1.21		$	0.28
	Diluted
	Average common shares outstanding	31,902			31,877		31,902			31,838
	Shares related to convertible debt	—			—		—			—
	Stock options and awards	164			24		107			9
	Average common shares assuming dilution	32,066			31,901		32,009			31,847
	Net earnings (loss) from continuing operations	$	(5,383	)	$	563	$	(35,580	)	$	374
	Net earnings from discontinued operations	$	21,485		$	2,301	$	74,401		$	8,746
	Net earnings	$	16,102		$	2,864	$	38,821		$	9,120
	Net earnings (loss) per common share from continuing operations *	$	(0.17	)	$	0.02	$	(1.12	)	$	0.01
	Net earnings per common share from discontinued operations	$	0.67		$	0.07	$	2.32		$	0.27
	Net earnings per common share *	$	0.5		$	0.09	$	1.2		$	0.28
	* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the period in which there was a net loss.
	At September 30, 2013, 4,375,829 and 4,406,045 shares associated with stock options were excluded from the average common shares assuming dilution for the three and nine months ended September 30, 2013 as they were anti-dilutive. At September 30, 2013, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $15.88 and $15.04 for the three and nine months ended September 30, 2013. At September 30, 2012, 4,639,809 and 4,679,093 shares associated with stock options were excluded from the average common shares assuming dilution for the three and nine months ended September 30, 2012 as they were anti-dilutive. At September 30, 2012, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $14.74 and $15.55 for the three and nine months ended September 30, 2012. For both the three and nine months ended September 30, 2013 and September 30, 2012, there were no shares necessary to settle a conversion spread on the convertible notes to be included in the common shares assuming dilution as the average market price of the company stock for these periods did not exceed the conversion price.

Concentration_Of_Credit_Risk

Concentration Of Credit Risk	9 Months Ended
	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'
Concentration Of Credit Risk	'
	Concentration of Credit Risk
	The company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to the company’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation which was $7,074,000 at September 30, 2013 to DLL for events of default under the leasing contracts, which total $50,570,000 at September 30, 2013. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements.
	Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers.
	In addition, the company is closely monitoring the roll-out of the second round of NCB, which became effective in 91 additional metropolitan statistical areas on July 1, 2013. At this early stage of the program, it is difficult to characterize the impact from NCB on the company's domestic home medical equipment business, as there continues to be uncertainty as the industry realigns and adjusts itself to the small number of bid contracts awarded.

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	Derivatives
	ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.
	Cash Flow Hedging Strategy
	The company uses derivative instruments in an attempt to manage its exposure to foreign currency exchange risk and interest rate risk. Foreign currency forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the company’s fixed and floating-rate borrowings.
	The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.
	During the first nine months of 2013 and 2012, the company was a party to interest rate swap agreements that qualified as cash flow hedges and effectively converted floating-rate debt to fixed-rate debt, so the company could avoid the risk of changes in market interest rates. The gains or losses on interest rate swaps are reflected in interest expense on the consolidated statement of comprehensive income (loss).
	To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months.
	The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 60% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $51,251,000 and $131,923,000 matured during the three and nine months ended September 30, 2013 compared to forward contracts with a total notional amount in USD of $50,244,000 and $134,402,000 that matured during the three and nine months ended September 30, 2012.
	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):
		September 30, 2013						December 31, 2012
		Notional			Unrealized			Notional			Unrealized
		Amount			Net Gain			Amount			Net Gain
					(Loss)						(Loss)
	USD / AUD	$	579		$	46		$	—		$	—
	USD / CAD	10,330			(85		)	17,620			(6		)
	USD / CNY	3,320			55			—			—
	USD / CHF	232			7			—			—
	USD / EUR	14,433			(368		)	59,510			(797		)
	USD / GBP	692			22			2,519			(3		)
	USD / NZD	465			4			—			—
	USD / SEK	3,499			115			—			—
	USD / MXP	2,846			11			6,954			141
	EUR / CAD	450			12			—			—
	EUR / CHF	1,555			17			—			—
	EUR / GBP	5,389			(40		)	2,077			46
	EUR / SEK	415			25			—			—
	EUR / NZD	1,748			23			5,749			105
	GBP / CHF	304			(8		)	—			—
	GBP / SEK	1,099			52			4,154			25
	DKK / SEK	1,051			(9		)	6,397			(47		)
	NOK / SEK	926			66			3,428			(4		)
		$	49,333		$	(55	)	$	108,408		$	(540	)
	Derivatives Not Qualifying or Designated for Hedge Accounting Treatment
	The company also utilizes foreign currency forward exchange contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward exchange contract. No material net gain or loss was realized by the company in 2013 or 2012 related to these contracts and the associated short-term intercompany trading receivables and payables.
	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2013 and 2012, respectively, and outstanding were as follows (in thousands USD):
		September 30, 2013						September 30, 2012
		Notional			Gain			Notional			Gain
		Amount			(Loss)			Amount			(Loss)
	CAD / USD	$	4,840		$	4		$	14,801		$	434
	EUR / USD	12,273			166			9,906			134
	CHF / USD	—			—			785			13
	DKK / USD	13,517			62			—			—
	GBP / USD	6,361			67			—			—
	NOK / USD	4,486			12			—			—
	NZD / USD	2,161			(8		)	3,146			40
	SEK / USD	6,502			32			—			—
	EUR / AUD	—			—			1,908			5
	EUR / CAD	—			—			239			(15		)
	EUR / DKK	—			—			(11,203		)	(27		)
	AUD / CAD	878			(4		)	3,056			(38		)
	AUD / EUR	1,788			248			—			—
	AUD / GBP	298			38			—			—
	AUD / NZD	—			—			1,048			15
	EUR / NZD	—			—			90			(10		)
	EUR / NOK	—			—			6			—
		$	53,104		$	617		$	23,782		$	551
	The fair values of the company’s derivative instruments were as follows (in thousands):
		September 30, 2013						December 31, 2012
		Assets			Liabilities			Assets			Liabilities
	Derivatives designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	$	626		$	681		$	375		$	915
	Interest rate swap contracts	—			22			—			316
	Derivatives not designated as hedging instruments under ASC 815
Foreign currency forward exchange contracts	685			68			687			142
Total derivatives	$	1,311		$	771		$	1,062		$	1,373
The fair values of the company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets.
The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands):
Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain  (Loss)			Amount of Gain (Loss)
relationships	(Loss) Recognized in OCI on Derivatives			Reclassified from			Recognized in Income on
	(Effective Portion)			Accumulated  OCI into			Derivatives  (Ineffective Portion
				Income (Effective			and Amount Excluded from
				Portion)			Effectiveness Testing)
Three months ended September 30, 2013
Foreign currency forward exchange contracts	$	(207	)	$	83		$	2
Interest rate swap contracts	33			(13		)	—
	$	(174	)	$	70		$	2
Nine months ended September 30, 2013
Foreign currency forward exchange contracts	$	505		$	(20	)	$	37
Interest rate swap contracts	433			(139		)	—
	$	938		$	(159	)	$	37
Three months ended September 30, 2012
Foreign currency forward exchange contracts	$	(2,522	)	$	1,241		$	(38	)
Interest rate swap contracts	(3		)	—			—
	$	(2,525	)	$	1,241		$	(38	)
Nine months ended September 30, 2012
Foreign currency forward exchange contracts	$	(2,956	)	$	2,706		$	(9	)
Interest rate swap contracts	(99		)	—			—
	$	(3,055	)	$	2,706		$	(9	)
Derivatives not designated as hedging							Amount of Gain (Loss)
instruments under ASC 815							Recognized in Income on Derivatives
Three months ended September 30, 2013
Foreign currency forward exchange contracts							$	361
Nine months ended September 30, 2013
Foreign currency forward exchange contracts							$	617
Three months ended September 30, 2012
Foreign currency forward exchange contracts							$	569
Nine months ended September 30, 2012
Foreign currency forward exchange contracts							$	551
The pre-tax gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward exchange contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. For the three and nine months ended September 30, 2013, net sales were increased by $54,000 and $496,000 and cost of product sold was increased by $128,000 and increased by $453,000 for net realized loss of $74,000 and $43,000. For the three and nine months ended September 30, 2012, net sales were decreased by $146,000 and increased by $49,000, respectively, and cost of product sold was decreased by $1,487,000 and $2,804,000, respectively, for net realized gains of $1,341,000 and $2,853,000, respectively.
The company recognized expense of $23,000 and $328,000 for the three and nine months ended September 30, 2013, respectively, compared to expense of $147,000 and $419,000 for the three and nine months ended September 30, 2012, respectively, related to interest rate swap agreements, which is reflected in interest expense on the consolidated statement of comprehensive income (loss).
Gains of $361,000 and $617,000 versus gains of $569,000 and $551,000 were recognized in selling, general and administrative (SG&A) expenses for the three and nine months ended September 30, 2013 and September 30, 2012, respectively, on ineffective forward contracts and forward contracts not designated as hedging instruments that are entered into to offset gains/losses also recorded in SG&A expenses on intercompany trade payables. Any gains/losses on the non designated hedging instruments were substantially offset by gains/losses also recorded in SG&A expenses on intercompany trade payables.
The company has entered into foreign currency forward exchange contracts and interest rate swap contracts (the “agreements”) with various bank counterparties, each of which are subject to provisions which are similar to a master netting agreement. The agreements provide for a net settlement payment in a single currency upon a default by the company. Furthermore, the agreements provide the counterparty with a right of set off in the event of a default that would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. The company does not present any derivatives on a net basis in its financial statements and all derivative balances presented are subject to provisions that are similar to master netting agreements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Values
	Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable.
	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands).
					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	30-Sep-13
	Forward Exchange Contracts—net	$	562		—			$	562			—
	Interest Rate Swap Agreements—net	(22		)	—			(22		)		—
	December 31, 2012:
	Forward Exchange Contracts—net	$	5		—			$	5			—
	Interest Rate Swap Agreements—net	(316		)	—			(316		)		—
	Forward Contracts: The company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany and third party sales or payments as well as intercompany loans. In an attempt to reduce this exposure, foreign currency forward exchange contracts are utilized and accounted for as hedging instruments. The contracts are used to hedge the following currencies: AUD, CAD, CHF, CNY, DKK, EUR, GBP, MXP, NOK, NZD, SEK and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign currency forward exchange contracts are based on quoted market prices for contracts with similar maturities.
	The carrying values and fair values of the company’s financial instruments are as follows (in thousands):
		September 30, 2013							December 31, 2012
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	32,625		$	32,625			$	38,791			$	38,791
	Other investments	1,190			1,190				1,171				1,171
	Installment receivables, net of reserves	2,236			2,236				2,594				2,594
	Long-term debt (including current maturities of long-term debt)	(56,069		)	(56,115		)		(234,802		)		(234,072		)
	Forward contracts in Other Current Assets	1,311			1,311				1,062				1,062
	Forward contracts in Accrued Expenses	(749		)	(749		)		(1,057		)		(1,057		)
	Interest rate swap agreements in Accrued Expenses	(22		)	(22		)		(316		)		(316		)
	The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions:
	Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value.
	Other investments: The company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return and the company does not have the ability to easily sell these investments.
	Installment receivables: The carrying value reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value.
	Long-term debt: Fair values for the company’s convertible debt and revolving credit facility are based upon the company’s estimate of the market for similar borrowing arrangements.
	Forward contracts and interest rate swaps: Fair values for the company’s foreign currency forward exchange contracts are based on quoted market prices, while the fair values of the interest rate swaps are based on model-derived calculations using inputs that are observable in active markets.

Business_Segments

Business Segments	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Business Segments	'
	Business Segments
	The company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific. The North America/HME segment sells each of three primary product lines, which includes: lifestyle, mobility and seating and respiratory therapy products. IPG sells or rents long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG. Each business segment sells to the home health care, retail and extended care markets.
	The company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance except for Asia/Pacific due to its significant intercompany sales volume relative to the segment.
	The information by segment is as follows (in thousands):
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2013			2012			2013			2012
	Revenues from external customers
	North America/HME	$	151,052		$	170,701		$	462,261		$	527,103
	Institutional Products Group	28,083			33,557			87,135			95,726
	Europe	150,265			141,705			429,650			401,721
	Asia/Pacific	11,776			15,555			38,327			53,217
	Consolidated	$	341,176		$	361,518		$	1,017,373		$	1,077,767
	Intersegment revenues
	North America/HME	$	20,501		$	24,813		$	59,735		$	81,985
	Institutional Products Group	1,254			1,941			4,243			5,471
	Europe	1,890			3,239			6,156			8,448
	Asia/Pacific	6,411			7,737			19,417			27,177
	Consolidated	$	30,056		$	37,730		$	89,551		$	123,081
	Restructuring charges before income taxes
	North America/HME	$	1,210		$	352		$	4,837		$	2,214
	Institutional Products Group	36			—			237			35
	Europe	542			481			722			772
	Asia/Pacific	96			342			1,202			721
	Consolidated	$	1,884		$	1,175		$	6,998		$	3,742
	Earnings (loss) before income taxes
	North America/HME	$	(10,191	)	$	(28	)	$	(33,593	)	$	8,086
	Institutional Products Group	1,009			579			1,955			4,820
	Europe	13,136			10,218			27,344			23,504
	Asia/Pacific	(2,233		)	(2,301		)	(9,871		)	(4,139		)
	All Other (1)	(6,354		)	(5,460		)	(17,515		)	(17,411		)
	Consolidated	$	(4,633	)	$	3,008		$	(31,680	)	$	14,860
	________________________
	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the “All Other” earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	General
	In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits in the United States have been referred to the company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures.
	As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting and other practices of health care suppliers and manufacturers are all subject to government scrutiny. The company's facilities are subject to periodic inspection by the FDA. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, including disqualification from Medicare and other reimbursement programs, which could have a material adverse effect on the company's business.
	FDA Matters
	The FDA regulates virtually all aspects of the development, testing, manufacturing, labeling, promotion, distribution and marketing of a medical device. The company's failure to comply with the regulatory requirements of the FDA and other applicable U.S. medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions. These sanctions include warning letters, civil penalties, criminal penalties, injunctions, consent decrees, product seizure or detention, product recalls and total or partial suspension of production.
	As previously disclosed, the company entered into a consent decree of injunction with the FDA related to the company's Corporate facility and its Taylor Street wheelchair manufacturing facility in Elyria, Ohio in December 2012. The consent decree was approved and made effective by the U.S. District Court for the Northern District of Ohio on December 21, 2012. The consent decree limits the company's manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility. The decree also temporarily limited design activities related to wheelchairs and power beds that take place at the impacted Elyria, Ohio facilities. The company is entitled to continue to produce from the Taylor Street manufacturing facility certain medically necessary products, as well as ongoing replacement, service and repair of products already in use, under terms delineated in the consent decree. Under the terms of the consent decree, in order to resume full operations at the impacted facilities, the company must successfully complete a third-party expert certification audit at the impacted Elyria facilities, which is comprised of three distinct reports that must be submitted to, and accepted by, the FDA. After the expert's final certification report is submitted to the FDA, along with the company’s own report as to its compliance as well as responses to any observations in the certification report, the FDA will perform an inspection of the company's Corporate and Taylor Street facilities to determine whether they are in compliance with the FDA's Quality System Regulation. The FDA has the authority to reinspect at any time. Once satisfied with the company's compliance, the FDA will provide written notification that the company is permitted to resume full operations at the impacted facilities.
	At the time of filing this Quarterly Report on Form 10-Q, the company has completed the first two of its third-party expert certification audits, and the FDA has found the results of both to be acceptable. In these reports, the third-party expert certified that the company's equipment and process validation procedures and its design control systems were compliant with the FDA's Quality System Regulation. As a result of the FDA's approval of the first certification audit report on May 13, 2013, the Taylor Street facility was able to resume supplying parts and components for the further manufacturing of medical devices at other company facilities. The company's receipt of the FDA's approval on the second certification audit report on July 15, 2013 resulted in the company being able to resume design activities related to power wheelchairs and power beds. The third, most comprehensive third-party certification audit is a comprehensive review of the company's compliance with the FDA's Quality System Regulation at the impacted Elyria facilities.
	The company is targeting to have the third, final and most comprehensive third-party certification report completed and filed with the FDA by mid-November 2013. There remains some scheduling issues and final work to complete in order to reach the targeted timing. Under the terms of the consent decree, the company must submit its own report to the FDA on the actions taken to correct any violations that may have been brought to the company’s attention by the expert and the actions the company has taken to ensure that the affected facilities are operated, and will continue to be operated, in conformity with the FDA’s Quality System Regulation. Within thirty (30) days after FDA’s receipt of the expert’s report and the company’s report, the FDA will commence its own inspection. It is not possible for the company to estimate the timing or potential response of the FDA's inspection and subsequent written notifications. Following successful completion of the FDA inspection and the company's receipt of written notification from the FDA that the Corporate and Taylor Street facilities appear to be in compliance, the company may resume full operations at those facilities.
	As described above, because the limitations on production will only be temporary in nature, and partial production will be allowed, the company does not anticipate any major repair, replacement or scrapping of its fixed assets at the Taylor Street manufacturing facility. Based on the company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection and with respect to future cash flows from production at the Taylor Street manufacturing facility, the company concluded that there is no impairment in the value of the fixed assets related to the Taylor Street manufacturing facility at September 30, 2013.
	The majority of the production from the Taylor Street facility is "made to order" custom wheelchairs for customers and, as a result, there was not a significant amount of finished goods inventory on hand at September 30, 2013. At the time of filing this Quarterly Report on Form 10-Q, the company believes that it would be able to obtain substantially all of the documentation required under the consent decree in order to complete the manufacture and shipment from the Taylor Street facility of the orders in the company's order fulfillment system and thus, the company concluded that there was not an impairment of the work in process and finished goods at the Taylor Street facility at September 30, 2013. Further, based on its analysis of the raw material inventory at the Taylor Street facility and the company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection, the company concluded that the value of the inventory was not excessive or impaired at September 30, 2013. However, if the company's expectations regarding the impacts of the limitations in the consent decree or the time frame for completion of the third-party expert certification audits and FDA inspection were to change, the company may, in future periods, conclude that an impairment exists with respect to its fixed assets or inventory at the Taylor Street facility.
	The North America/HME segment is the segment primarily impacted by the limitations in the FDA consent decree. However, the Asia/Pacific segment also is negatively affected as a result of the consent decree due to the lower sales volume of microprocessor controllers. During 2012, before the effective date of the consent decree, the company started to experience decreases in net sales in this segment. Those decreases were primarily related to delays in new product introductions, uncertainty on the part of the company's customers as they coped with prepayment reviews and post-payment audits by the Centers for Medicare and Medicaid Services ("CMS") and contemplated their participation in the next round of National Competitive Bidding ("NCB"), and, the company believes, uncertainty regarding the resolution of the consent decree which limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. The negative effect of the consent decree on customer orders and net sales has been considerable, and the company expects to experience continued low levels in net sales as a result of the limitations imposed by the consent decree. The company expects to continue to experience lower levels of net sales in the segment at least until it has successfully completed the previously-described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the company may resume full operations at the Corporate and Taylor Street facilities. Even after the company is permitted to resume full operations at the affected facilities, it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, the limitations in the consent decree had, and likely will continue to have, a material adverse effect on the company's business, financial condition and results of operations.
	In the second quarter of 2013, the company recorded a warranty reserve of $3,800,000 related to a power wheelchair joystick recall. The estimate was calculated based on discussions with the FDA and the company's resultant expectation that an end user notification was not adequate and that a recall would be initiated involving the replacement of the potentially affected joysticks, which are sold globally. The power wheelchair joystick performance issue relates to an anomaly discovered in a fraction of a percentage of the components in the field. The company's warranty reserve for this power wheelchair component recall is based upon estimates derived from the company's actual experience with prior recalls. No changes were made in the warranty reserve recorded related to this issue in the third quarter of 2013. However, the reserve is subject to adjustment as new developments or experiences change the company's estimate of the total cost of this matter.
	For additional information regarding the consent decree, please see the following sections of the company's Annual Report on Form 10-K for the year ending December 31, 2012: Item 1. Business - Government Regulation and Item 1A. Risk Factors and the following sections of this Quarterly Report on Form 10-Q: Item 1. Legal Proceedings; and Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook and - Liquidity and Capital Resources.
	In addition, in December 2010, the company received a warning letter from the FDA related to quality system processes and procedures at the company's Sanford, Florida facility. The company has taken actions which it believes address all of the FDA's concerns in the warning letter. However, the results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA warning letter could materially and adversely affect the company's business, financial condition, and results of operations.
	Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations.

Supplemental_Guarantor_Informa

Supplemental Guarantor Information	9 Months Ended
	Sep. 30, 2013
Supplemental Guarantor Information [Abstract]	'
Supplemental Guarantor Information	'
	Supplemental Guarantor Information
	Effective February 12, 2007, substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Convertible Senior Subordinated Debentures due 2027 (the “Debentures”) with an original aggregate principal amount of $135,000,000. The majority of the company’s subsidiaries are not guaranteeing the indebtedness of the Debentures (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Debentures and each of the Guarantor Subsidiaries are directly or indirectly 100%-owned subsidiaries of the company. Specifically, the Debentures are guaranteed on an unsecured senior subordinated basis by all of our existing domestic subsidiaries (other than our captive insurance subsidiary and any receivables subsidiaries) and certain future direct and indirect 100% owned domestic subsidiaries. All of the guarantors are released and relieved of any liability under such guarantees upon the satisfaction and discharge of the indenture governing the debentures and the payment in full of the debentures. Additionally, in the event any subsidiary guarantor no longer guarantees any of our existing or future senior debt incurred in a public or private U.S. capital markets transaction, such guarantor shall be released and relieved of any liability which it has under the indenture governing the debentures.
	Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented.
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Three month period ended September 30, 2013	(in thousands)
	Net sales	$	60,641		$	119,548		$	184,299		$	(23,312	)	$	341,176
	Cost of products sold	52,454			86,978			128,232			(23,312		)	244,352
	Gross Profit	8,187			32,570			56,067			—			96,824
	Selling, general and administrative expenses	29,046			25,363			44,310			—			98,719
	Charge related to restructuring activities	1,597			36			251			—			1,884
	Asset write-downs to intangibles and investments	—			167			—			—			167
	Income (loss) from equity investee	32,513			8,935			22			(41,470		)	—
	Interest expense (income)—net	(603		)	1,213			77			—			687
	Earnings (Loss) from Continuing Operations before Income Taxes	10,660			14,726			11,451			(41,470		)	(4,633		)
	Income taxes (benefit)	(5,442		)	—			6,192			—			750
	Net Earnings (Loss) from Continuing Operations	16,102			14,726			5,259			(41,470		)	(5,383		)
	Net Earnings from Discontinued Operations	—			21,485			—			—			21,485
	Net Earnings (loss)	$	16,102		$	36,211		$	5,259		$	(41,470	)	$	16,102
	Other Comprehensive Income (Loss), Net of Tax	9,874			220			10,135			(10,355		)	9,874
	Comprehensive Income (Loss)	$	25,976		$	36,431		$	15,394		$	(51,825	)	$	25,976
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Three month period ended September 30, 2012	(in thousands)
	Net sales	$	90,406		$	116,339		$	183,801		$	(29,028	)	$	361,518
	Cost of products sold	70,600			83,685			126,852			(29,031		)	252,106
	Gross Profit	19,806			32,654			56,949			3			109,412
	Selling, general and administrative expenses	33,712			20,356			45,492			3,721			103,281
	Charge related to restructuring activities	334			18			823			—			1,175
	Loss on debt extinguishment including debt finance charges and associated fees	—			—			—			—			—
	Income (loss) from equity investee	17,302			(4,264		)	228			(13,266		)	—
	Interest expense (income)—net	(1,024		)	2,201			771			—			1,948
	Earnings (Loss) from Continuing Operations before Income Taxes	4,086			5,815			10,091			(16,984		)	3,008
	Income taxes (benefit)	1,222			(3,028		)	4,251			—			2,445
	Net Earnings (Loss) from Continuing Operations	2,864			8,843			5,840			(16,984		)	563
	Net Earnings from Discontinued Operations	—			2,301			—			—			2,301
	Net Earnings (loss)	$	2,864		$	11,144		$	5,840		$	(16,984	)	$	2,864
	Other Comprehensive Income (Loss), Net of Tax	14,518			3,164			11,412			(14,576		)	14,518
	Comprehensive Income (Loss)	$	17,382		$	14,308		$	17,252		$	(31,560	)	$	17,382
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Nine month period ended September 30, 2013
	Net sales	$	186,453		$	364,005		$	535,805		$	(68,890	)	$	1,017,373
	Cost of products sold	159,884			264,501			378,287			(69,264		)	733,408
	Gross Profit	26,569			99,504			157,518			374			283,965
	Selling, general and administrative expenses	99,338			72,370			131,640			2,694			306,042
	Charge related to restructuring activities	5,078			49			1,871			—			6,998
	Asset write-downs to intangibles and investments	—			167			—			—			167
	Income (loss) from equity investee	105,501			21,472			(93		)	(126,880		)	—
	Interest expense (income)—net	(1,418		)	3,141			715			—			2,438
	Earnings (Loss) from Continuing Operations before Income Taxes	29,072			45,249			23,199			(129,200		)	(31,680		)
	Income taxes (benefit)	(9,749		)	—			13,649			—			3,900
	Net Earnings (Loss) from Continuing Operations	38,821			45,249			9,550			(129,200		)	(35,580		)
	Net Earnings from Discontinued Operations	—			74,401			—			—			74,401
	Net Earnings (loss)	$	38,821		$	119,650		$	9,550		$	(129,200	)	$	38,821
	Other Comprehensive Income (Loss), Net of Tax	1,845			(415		)	2,228			(1,813		)	1,845
	Comprehensive Income (Loss)	$	40,666		$	119,235		$	11,778		$	(131,013	)	$	40,666
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Nine month period ended September 30, 2012	(in thousands)
Net sales	$	275,742		$	355,378		$	540,535		$	(93,888	)	$	1,077,767
Cost of products sold	211,115			256,854			371,855			(93,455		)	746,369
Gross Profit	64,627			98,524			168,680			(433		)	331,398
Selling, general and administrative expenses	99,736			64,452			138,207			4,360			306,755
Charge related to restructuring activities	2,085			39			1,618			—			3,742
Loss on debt extinguishment including debt finance charges and associated fees	312			—			—			—			312
Income (loss) from equity investee	45,175			1,954			391			(47,520		)	—
Interest expense (income)—net	(3,041		)	6,396			2,374			—			5,729
Earnings (Loss) from Continuing Operations before Income Taxes	10,710			29,591			26,872			(52,313		)	14,860
Income taxes (benefit)	1,590			(5,164		)	18,060			—			14,486
Net Earnings (Loss) from Continuing Operations	9,120			34,755			8,812			(52,313		)	374
Net Earnings from Discontinued Operations	—			8,746			—			—			8,746
Net Earnings (loss)	$	9,120		$	43,501		$	8,812		$	(52,313	)	$	9,120
Other Comprehensive Income (Loss), Net of Tax	(24,673		)	3,179			(27,878		)	24,699			(24,673		)
Comprehensive Income (Loss)	$	(15,553	)	$	46,680		$	(19,066	)	$	(27,614	)	$	(15,553	)
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
September 30, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	3,148		$	—		$	29,477		$	—		$	32,625
Trade receivables, net	69,633			29,453			92,378			—			191,464
Installment receivables, net	—			569			991			—			1,560
Inventories, net	37,797			27,784			104,970			(3,183		)	167,368
Intercompany advances, net	5,055			664			43,145			(48,864		)	—
Other current assets	6,371			570			34,129			(7,240		)	33,830
Total Current Assets	122,004			59,040			305,090			(59,287		)	426,847
Investment in subsidiaries	1,433,252			440,197			—			(1,873,449		)	—
Intercompany advances, net	937,116			1,592,785			178,180			(2,708,081		)	—
Other Assets	38,961			463			903			—			40,327
Other Intangibles	553			19,139			45,413			—			65,105
Property and Equipment, net	36,783			18,621			52,987			—			108,391
Goodwill	—			16,660			434,067			—			450,727
Total Assets	$	2,568,669		$	2,146,905		$	1,016,640		$	(4,640,817	)	$	1,091,397
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	50,462		$	8,237		$	58,985		$	—		$	117,684
Accrued expenses	30,864			17,737			89,118			(7,240		)	130,479
Accrued income taxes	5,540			—			1,661			—			7,201
Intercompany advances, net	41,889			1,481			5,494			(48,864		)	—
Short-term debt and current maturities of long-term obligations	556			7			731			—			1,294
Total Current Liabilities	129,311			27,462			155,989			(56,104		)	256,658
Long-Term Debt	22,476			82			32,217			—			54,775
Other Long-Term Obligations	54,176			—			60,597			—			114,773
Intercompany advances, net	1,707,515			936,722			63,844			(2,708,081		)	—
Total Shareholders’ Equity	655,191			1,182,639			703,993			(1,876,632		)	665,191
Total Liabilities and Shareholders’ Equity	$	2,568,669		$	2,146,905		$	1,016,640		$	(4,640,817	)	$	1,091,397
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
December 31, 2012	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	5,774		$	1,018		$	31,999		$	—		$	38,791
Trade receivables, net	71,622			37,223			89,946			—			198,791
Installment receivables, net	—			829			1,359			—			2,188
Inventories, net	40,278			31,455			114,169			(2,656		)	183,246
Intercompany advances, net	4,077			763			64,570			(69,410		)	—
Other current assets	12,727			473			34,606			(6,030		)	41,776
Assets held for sale - current	—			103,157			—			—			103,157
Total Current Assets	134,478			174,918			336,649			(78,096		)	567,949
Investment in subsidiaries	1,536,898			523,176			6,888			(2,066,962		)	—
Intercompany advances, net	863,973			1,468,405			173,903			(2,506,281		)	—
Other Assets	41,006			314			942			—			42,262
Other Intangibles	663			22,211			48,778			—			71,652
Property and Equipment, net	39,911			19,957			58,363			—			118,231
Goodwill	—			32,937			429,263			—			462,200
Total Assets	$	2,616,929		$	2,241,918		$	1,054,786		$	(4,651,339	)	$	1,262,294
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	63,812		$	9,465		$	59,771		$	—		$	133,048
Accrued expenses	36,716			18,155			86,348			(6,030		)	135,189
Accrued income taxes	1,545			—			1,168			—			2,713
Intercompany advances, net	61,368			2,369			5,673			(69,410		)	—
Short-term debt and current maturities of long-term obligations	4,552			7			868			—			5,427
Liabilities held for sale - current	—			23,358			—			—			23,358
Total Current Liabilities	167,993			53,354			153,828			(75,440		)	299,735
Long-Term Debt	223,014			143			6,218			—			229,375
Other Long-Term Obligations	52,957			—			59,238			—			112,195
Intercompany advances, net	1,551,976			863,585			90,720			(2,506,281		)	—
Total Shareholders’ Equity	620,989			1,324,836			744,782			(2,069,618		)	620,989
Total Liabilities and Shareholders’ Equity	$	2,616,929		$	2,241,918		$	1,054,786		$	(4,651,339	)	$	1,262,294
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Nine month period ended September 30, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	35,179		$	(81,077	)	$	(20,736	)	$	65,389		$	(1,245	)
Investing Activities
Purchases of property and equipment	(3,234		)	(3,611		)	(4,241		)	—			(11,086		)
Proceeds from sale of property and equipment	—			11			845			—			856
Proceeds from sale of business	—			187,552			—			—			187,552
Other long-term assets	783			—			166			—			949
Other	171,353			(103,417		)	—			(68,083		)	(147		)
Net Cash Provided (Used) for Investing Activities	168,902			80,535			(3,230		)	(68,083		)	178,124
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	226,189			—			23,935			—			250,124
Payments on revolving lines of credit and long-term borrowings	(431,709		)	(476		)	—			—			(432,185		)
Payment of dividends	(1,187		)	—			(2,694		)	2,694			(1,187		)
Net Cash Provided (Used) by Financing Activities	(206,707		)	(476		)	21,241			2,694			(183,248		)
Effect of exchange rate changes on cash	—			—			203			—			203
Decrease in cash and cash equivalents	(2,626		)	(1,018		)	(2,522		)	—			(6,166		)
Cash and cash equivalents at beginning of year	5,774			1,018			31,999			—			38,791
Cash and cash equivalents at end of period	$	3,148		$	—		$	29,477		$	—		$	32,625
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Nine month period ended September 30, 2012	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	18,260		$	5,405		$	7,527		$	(4,370	)	$	26,822
Investing Activities
Purchases of property and equipment	(1,353		)	(7,854		)	(5,568		)	—			(14,775		)
Proceeds from sale of property and equipment	18			14			65			—			97
Other long-term assets	(214		)	—			623			—			409
Other	(158		)	(117		)	56			—			(219		)
Net Cash Used for Investing Activities	(1,707		)	(7,957		)	(4,824		)	—			(14,488		)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	252,590			3,113			—			—			255,703
Payments on revolving lines of credit and long-term borrowings	(266,182		)	—			(539		)	—			(266,721		)
Payment of financing costs	(1		)	—			—			—			(1		)
Payment of dividends	(1,183		)	—			(4,370		)	4,370			(1,183		)
Net Cash Provided (Used) by Financing Activities	(14,776		)	3,113			(4,909		)	4,370			(12,202		)
Effect of exchange rate changes on cash	—			—			226			—			226
Increase (Decrease) in cash and cash equivalents	1,777			561			(1,980		)	—			358
Cash and cash equivalents at beginning of year	3,642			2,104			29,178			—			34,924
Cash and cash equivalents at end of period	$	5,419		$	2,665		$	27,198		$	—		$	35,282

Accounting_Policies_Policies

Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of September 30, 2013, the results of its operations for the three and nine months ended September 30, 2013 and changes in its cash flow for the nine months ended September 30, 2013 and 2012, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using an August 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated.  The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	'
	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
Stock-Based Compensation	'
	Stock-Based Compensation Plans: The company accounts for share-based compensation under the provisions of Compensation-Stock Compensation, ASC 718. The company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted. The company continues to use a Black-Scholes valuation model.
	Stock options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods. The amounts of stock-based compensation expense recognized were as follows (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	2,147	$	2,208	$	4,721	$	5,198
	The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan and the 2013 Equity Compensation Plan. Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the company's Business Segment Note to the Consolidated Financial Statements.

Accounting_Policies_Tables

Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The amounts of stock-based compensation expense recognized were as follows (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	2,147	$	2,208	$	4,721	$	5,198

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended			9 Months Ended
	Dec. 31, 2012			Sep. 30, 2013
	ISG [Member]			Champion [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'			'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	'			'
	The assets and liabilities of ISG that were sold are shown as held for sale in the company's Consolidated Balance Sheets and are comprised of the following (in thousands):
					August 6,		December 31,
		December 31,			2013		2012
		2012
				Trade receivables, net	$	3,030	$	2,375
	Trade receivables, net	$	44,196
				Inventories, net	1,689		1,617
	Inventories, net	25,165
				Other current assets	92		21
	Other current assets	9,355
				Property and Equipment, net	309		237
	Property and Equipment, net	1,368
				Goodwill	16,277		16,277
	Goodwill	23,073
				Assets sold	$	21,397	$	20,527
	Assets held for sale - current	$	103,157
				Accounts payable	$	936	$	475
	Accounts payable	$	17,692
				Accrued expenses	352		318
	Accrued expenses	4,602
				Accrued income taxes	—		200
	Accrued income taxes	1,064
				Liabilities sold	$	1,288	$	993
	Liabilities held for sale - current	$	23,358

Receivables_Tables

Receivables (Tables)	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Installment Receivables [Table Text Block]	'
	Installment receivables consist of the following (in thousands):
		September 30, 2013									December 31, 2012
		Current			Long-			Total			Current			Long-			Total
					Term									Term
	Installment receivables	$	3,554		$	2,394		$	5,948		$	4,982		$	1,506		$	6,488
	Less: Unearned interest	(70		)	—			(70		)	(71		)	—			(71		)
		3,484			2,394			5,878			4,911			1,506			6,417
	Allowance for doubtful accounts	(1,924		)	(1,718		)	(3,642		)	(2,723		)	(1,100		)	(3,823		)
		$	1,560		$	676		$	2,236		$	2,188		$	406		$	2,594
Schedule of Installment Receivables Allowance for Doubtful Accounts [Table Text Block]	'
	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):
		Nine Months Ended June 30, 2013			Year Ended December 31, 2012
	Balance as of beginning of period	$	3,823		$	4,273
	Current period provision	943			458
	Direct write-offs charged against the allowance	(1,124		)	(908		)
	Balance as of end of period	$	3,642		$	3,823
Schedule of Installment Receivables by Class [Table Text Block]	'
	Installment receivables by class as of September 30, 2013 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	4,510		$	4,510		$	3,477		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,273			1,203			—			76
	Impaired Installment receivables with a related allowance recorded	165			165			165			—
	Total Canadian Installment Receivables	$	1,438		$	1,368		$	165		$	76
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,273			1,203			—			76
	Impaired Installment receivables with a related allowance recorded	4,675			4,675			3,642			—
	Total Installment Receivables	$	5,948		$	5,878		$	3,642		$	76
	Installment receivables by class as of December 31, 2012 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	4,508		$	4,508		$	3,365		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,522			1,451			—			120
	Impaired Installment receivables with a related allowance recorded	458			458			458			—
	Total Canadian Installment Receivables	$	1,980		$	1,909		$	458		$	120
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,522			1,451			—			120
	Impaired Installment receivables with a related allowance recorded	4,966			4,966			3,823			—
	Total Installment Receivables	$	6,488		$	6,417		$	3,823		$	120
Schedule of Aging of Installment Receivables [Table Text Block]	'
	The aging of the company’s installment receivables was as follows (in thousands):
		September 30, 2013									31-Dec-12
		Total			U.S.			Canada			Total			U.S.			Canada
	Current	$	1,218		$	—		$	1,218		$	1,467		$	—		$	1,467
	0-30 Days Past Due	9			—			9			43			—			43
	31-60 Days Past Due	6			—			6			2			—			2
	61-90 Days Past Due	—			—			—			—			—			—
	90+ Days Past Due	4,715			4,510			205			4,976			4,508			468
		$	5,948		$	4,510		$	1,438		$	6,488		$	4,508		$	1,980

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory, Net [Abstract]	'
Inventories [Table Text Block]	'
	Inventories consist of the following (in thousands):
		30-Sep-13		31-Dec-12
	Finished goods	$	90,422	$	94,675
	Raw materials	61,642		71,596
	Work in process	15,304		16,975
		$	167,368	$	183,246

Other_Current_Assets_Tables

Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Other Current Assets [Abstract]	'
Schedule of Other Assets [Table Text Block]	'
	Other current assets consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Value added tax receivables	$	15,004	$	18,002
	Recoverable income taxes	3,457		6,192
	Derivatives (foreign currency forward contracts)	1,311		1,062
	Prepaid insurance	300		2,241
	Prepaids and other current assets	13,758		14,279
		$	33,830	$	41,776

Other_LongTerm_Assets_Tables

Other Long-Term Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Schedule of Other Assets, Noncurrent [Table Text Block]	'
	Other long-term assets consist of the following (in thousands):
		September 30, 2013		December 31, 2012
	Cash surrender value of life insurance policies	$	35,772	$	36,375
	Deferred Financing Fees	1,356		2,728
	Investments	1,190		1,171
	Long-term installment receivables	676		406
	Other	1,333		1,582
		$	40,327	$	42,262

Property_And_Equipment_Tables

Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		September 30, 2013			December 31, 2012
	Machinery and equipment	$	356,935		$	356,512
	Land, buildings and improvements	90,234			95,047
	Furniture and fixtures	12,998			13,397
	Leasehold improvements	14,886			14,975
		475,053			479,931
	Less allowance for depreciation	(366,662		)	(361,700		)
		$	108,391		$	118,231

Other_Intangibles_Tables

Other Intangibles (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Definite and Indefinite Lived Intangible Assets [Table Text Block]	'
	Th

Current_Liabilities_Tables

Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of accruals for the following (in thousands):
		September 30, 2013		December 31, 2012
	Salaries and wages	$	37,480	$	41,813
	Taxes other than income taxes, primarily Value Added Taxes	23,225		24,600
	Warranty cost	25,020		21,451
	Freight	7,806		7,853
	Professional	7,355		7,595
	Product liability, current portion	3,572		3,323
	Rebates	2,136		3,635
	Insurance	2,726		2,674
	Interest	921		1,268
	Derivative liabilities	771		1,373
	Severance	3,481		5,211
	Other items, principally trade accruals	15,986		14,393
		$	130,479	$	135,189

Warrany_Costs_Tables

Warrany Costs (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities, Current [Abstract]	'
Accrued Warranty Costs [Table Text Block]	'
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):
	Balance as of January 1, 2013	$	21,451
	Warranties provided during the period	7,843
	Settlements made during the period	(8,741		)
	Changes in liability for pre-existing warranties during the period, including expirations	4,467
	Balance as of September 30, 2013	$	25,020

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	The liability components of the company’s convertible debt consist of the following (in thousands):
		September 30, 2013			December 31, 2012
	Principal amount of liability component	$	13,350		$	13,350
	Unamortized discount	(2,874		)	(3,341		)
	Net carrying amount of liability component	$	10,476		$	10,009
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Debt consists of the following (in thousands):
		September 30, 2013			December 31, 2012
	Senior secured revolving credit facility, due in October 2015	$	38,968		$	217,494
	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,476			10,009
	Other notes and lease obligations	6,625			7,299
		56,069			234,802
	Less current maturities of long-term debt	(1,294		)	(5,427		)
		$	54,775		$	229,375

Shareholders_Equity_Transactio1

Shareholders' Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes information about stock option activity for the nine months ended September 30, 2013:
		September 30, 2013				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2013	4,664,634				$	26.21
	Granted	756,700				14.47
	Exercised	—				—
	Canceled	(792,584		)		28.74
	Options outstanding at September 30, 2013	4,628,750				$	23.86
	Options exercise price range at September 30, 2013	$ 12.42 to
		$	47.8
	Options exercisable at September 30, 2013	3,070,364
	Options available for grant at September 30, 2013*	4,460,337
Schedule of Share-based Compensation, Stock Options Outstanding [Table Text Block]	'
	The following table summarizes information about stock options outstanding at September 30, 2013:
		Options Outstanding							Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average		Number	Weighted Average
		Outstanding			Remaining		Exercise Price		Exercisable	Exercise Price
		At 9/30/13			Contractual Life (Years)				At 9/30/13
	$ 12.42 – $15.00	1,354,435			9.2		$	13.95	166,045	$	13.38
	$ 15.01 – $25.00	1,613,291			5.6		22.51		1,364,559	22.21
	$ 25.01 – $35.00	950,109			5.7		25.81		828,846	25.85
	$ 35.01 – $47.80	710,915			1.4		43.21		710,914	43.21
	Total	4,628,750			6		$	23.86	3,070,364	$	27.57

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Foreign Currency		Long-Term Notes		Defined Benefit Plans		Derivatives		Total
	June 30, 2013	117,817		(6,743	)	(6,419	)	59		104,714
	OCI before reclassifications	17,852		(8,062	)	265		(197	)	9,858
	Amount reclassified from accumulated OCI	—		—		(62	)	78		16
	Net current-period OCI	17,852		(8,062	)	203		(119	)	9,874
	30-Sep-13	135,669		(14,805	)	(6,216	)	(60	)	114,588
	Changes in OCI during the nine months ended September 30, 2013 were as follows (in thousands):
		Foreign Currency		Long-Term Notes		Defined Benefit Plans		Derivatives		Total
	December 31, 2012	117,465		2,845		(6,785	)	(782	)	112,743
	OCI before reclassifications	18,204		(17,650	)	750		650		1,954
	Amount reclassified from accumulated OCI	—		—		(181	)	72		(109	)
	Net current-period OCI	18,204		(17,650	)	569		722		1,845
	30-Sep-13	135,669		(14,805	)	(6,216	)	(60	)	114,588
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
	Reclassifications out of accumulated OCI for the three and nine months ended September 30, 2013 were as follows (in thousands):
		Amount reclassified from OCI				Affected line item in the Statement of Comprehensive Income (Loss)
		Three Months Ended September 30, 2013		Nine Months Ended September 30, 2013
	Defined Benefit Plans
	Service and interest costs	(64	)	(187	)	Selling, General and Administrative
	Tax	2		6		Income Taxes
	Total after tax	(62	)	(181	)
	Derivatives
	Foreign currency forward contracts hedging sales	(54	)	(496	)	Net Sales
	Foreign currency forward contracts hedging purchases	128		453		Cost of Products Sold
	Interest rate swaps	13		139		Interest Expense
	Total before tax	87		96
	Tax	(9	)	(24	)	Income Taxes
	Total after tax	78		72

Charges_Related_To_Restructuri1

Charges Related To Restructuring Activities (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs [Table Text Block]	'
	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2010 Balance
	Total	$	—		$	—		$	—		$	—		$	—
	Charges
	NA/HME	4,755			—			—			4			4,759
	IPG	123			—			—			—			123
	Europe	3,288			277			1,788			113			5,466
	Asia/Pacific	186			—			—			—			186
	Total	8,352			277			1,788			117			10,534
	Payments
	NA/HME	(1,663		)	—			—			(4		)	(1,667		)
	IPG	(52		)	—			—			—			(52		)
	Europe	(1,546		)	(277		)	(1,714		)	(113		)	(3,650		)
	Asia/Pacific	(186		)	—			—			—			(186		)
	Total	(3,447		)	(277		)	(1,714		)	(117		)	(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092			—			—			—			3,092
	IPG	71			—			—			—			71
	Europe	1,742			—			74			—			1,816
	Asia/Pacific	—			—			—			—			—
	Total	4,905			—			74			—			4,979
	Charges
	NA/HME	4,242			—			5			—			4,247
	IPG	35			—			—			—			35
	Europe	817			—			53			1,223			2,093
	Asia/Pacific	1,681			491			1,667			1,181			5,020
	Total	6,775			491			1,725			2,404			11,395
	Payments
	NA/HME	(3,587		)	—			(5		)	—			(3,592		)
	IPG	(106		)	—			—			—			(106		)
	Europe	(1,964		)	—			(127		)	(1,223		)	(3,314		)
	Asia/Pacific	(812		)	(340		)	(42		)	(1,175		)	(2,369		)
	Total	$	(6,469	)	$	(340	)	$	(174	)	$	(2,398	)	$	(9,381	)
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2012 Balance
	NA/HME	$	3,747		$	—		$	—		$	—		$	3,747
	IPG	—			—			—			—			—
	Europe	595			—			—			—			595
	Asia/Pacific	869			151			1,625			6			2,651
	Total	5,211			151			1,625			6			6,993
	Charges
	NA/HME	1,679			—			—			—			1,679
	IPG	189			—			—			—			189
	Europe	115			—			—			—			115
	Asia/Pacific	453			—			86			—			539
	Total	2,436			—			86			—			2,522
	Payments
	NA/HME	(2,005		)	—			—			—			(2,005		)
	IPG	(17		)	—			—			—			(17		)
	Europe	(461		)	—			—			—			(461		)
	Asia/Pacific	(618		)	(151		)	(766		)	(4		)	(1,539		)
	Total	(3,101		)	(151		)	(766		)	(4		)	(4,022		)
	March 31, 2013 Balance
	NA/HME	3,421			—			—			—			3,421
	IPG	172			—			—			—			172
	Europe	249			—			—			—			249
	Asia/Pacific	704			—			945			2			1,651
		4,546			—			945			2			5,493
	Charges
	NA/HME	1,948			—			—			—			1,948
IPG	13			—			—			—			13
Europe	65			—			—			—			65
Asia/Pacific	480			—			86			—			566
Total	2,506			—			86			—			2,592
Payments
NA/HME	(1,795		)	—			—			—			(1,795		)
IPG	(26		)	—			—			—			(26		)
Europe	(182		)	—			—			—			(182		)
Asia/Pacific	(129		)	—			(49		)	(2		)	(180		)
Total	(2,132		)	—			(49		)	(2		)	(2,183		)
June 30, 2013 Balance
NA/HME	3,574			—			—			—			3,574
IPG	159			—			—			—			159
Europe	132			—			—			—			132
Asia/Pacific	1,055			—			982			—			2,037
	$	4,920		$	—		$	982		$	—		$	5,902
	Severance			Product Line			Contract			Other			Total
				Discontinuance			Terminations
Charges
NA/HME	$	644		$	—		$	213		$	353		$	1,210
IPG	36			—			—			—			36
Europe	739			—			—			(198		)	541
Asia/Pacific	15			—			79			3			97
Total	1,434			—			292			158			1,884
Payments
NA/HME	(1,624		)	—			(85		)	(305		)	(2,014		)
IPG	(52		)	—			—			—			(52		)
Europe	(157		)	—			—			198			41
Asia/Pacific	(1,040		)	—			(557		)	(3		)	(1,600		)
Total	(2,873		)	—			(642		)	(110		)	(3,625		)
September 30, 2013 Balance
NA/HME	2,594			—			128			48			2,770
IPG	143			—			—			—			143
Europe	714			—			—			—			714
Asia/Pacific	30			—			504			—			534
	$	3,481		$	—		$	632		$	48		$	4,161

Net_Earnings_Loss_Per_Common_S1

Net Earnings (Loss) Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.
	(In thousands except per share data)	For the Three Months Ended September 30,					For the Nine Months Ended September 30,
		2013			2012		2013			2012
	Basic
	Average common shares outstanding	31,902			31,877		31,902			31,838
	Net earnings (loss) from continuing operations	$	(5,383	)	$	563	$	(35,580	)	$	374
	Net earnings from discontinued operations	$	21,485		$	2,301	$	74,401		$	8,746
	Net earnings	$	16,102		$	2,864	$	38,821		$	9,120
	Net earnings (loss) per common share from continuing operations	$	(0.17	)	$	0.02	$	(1.12	)	$	0.01
	Net earnings per common share from discontinued operations	$	0.67		$	0.07	$	2.33		$	0.27
	Net earnings per common share	$	0.5		$	0.09	$	1.21		$	0.28
	Diluted
	Average common shares outstanding	31,902			31,877		31,902			31,838
	Shares related to convertible debt	—			—		—			—
	Stock options and awards	164			24		107			9
	Average common shares assuming dilution	32,066			31,901		32,009			31,847
	Net earnings (loss) from continuing operations	$	(5,383	)	$	563	$	(35,580	)	$	374
	Net earnings from discontinued operations	$	21,485		$	2,301	$	74,401		$	8,746
	Net earnings	$	16,102		$	2,864	$	38,821		$	9,120
	Net earnings (loss) per common share from continuing operations *	$	(0.17	)	$	0.02	$	(1.12	)	$	0.01
	Net earnings per common share from discontinued operations	$	0.67		$	0.07	$	2.32		$	0.27
	Net earnings per common share *	$	0.5		$	0.09	$	1.2		$	0.28

Derivatives_Tables

Derivatives (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	'
	oreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):
		September 30, 2013						December 31, 2012
		Notional			Unrealized			Notional			Unrealized
		Amount			Net Gain			Amount			Net Gain
					(Loss)						(Loss)
	USD / AUD	$	579		$	46		$	—		$	—
	USD / CAD	10,330			(85		)	17,620			(6		)
	USD / CNY	3,320			55			—			—
	USD / CHF	232			7			—			—
	USD / EUR	14,433			(368		)	59,510			(797		)
	USD / GBP	692			22			2,519			(3		)
	USD / NZD	465			4			—			—
	USD / SEK	3,499			115			—			—
	USD / MXP	2,846			11			6,954			141
	EUR / CAD	450			12			—			—
	EUR / CHF	1,555			17			—			—
	EUR / GBP	5,389			(40		)	2,077			46
	EUR / SEK	415			25			—			—
	EUR / NZD	1,748			23			5,749			105
	GBP / CHF	304			(8		)	—			—
	GBP / SEK	1,099			52			4,154			25
	DKK / SEK	1,051			(9		)	6,397			(47		)
	NOK / SEK	926			66			3,428			(4		)
		$	49,333		$	(55	)	$	108,408		$	(540	)
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2013 and 2012, respectively, and outstanding were as follows (in thousands USD):
		September 30, 2013						September 30, 2012
		Notional			Gain			Notional			Gain
		Amount			(Loss)			Amount			(Loss)
	CAD / USD	$	4,840		$	4		$	14,801		$	434
	EUR / USD	12,273			166			9,906			134
	CHF / USD	—			—			785			13
	DKK / USD	13,517			62			—			—
	GBP / USD	6,361			67			—			—
	NOK / USD	4,486			12			—			—
	NZD / USD	2,161			(8		)	3,146			40
	SEK / USD	6,502			32			—			—
	EUR / AUD	—			—			1,908			5
	EUR / CAD	—			—			239			(15		)
	EUR / DKK	—			—			(11,203		)	(27		)
	AUD / CAD	878			(4		)	3,056			(38		)
	AUD / EUR	1,788			248			—			—
	AUD / GBP	298			38			—			—
	AUD / NZD	—			—			1,048			15
	EUR / NZD	—			—			90			(10		)
	EUR / NOK	—			—			6			—
		$	53,104		$	617		$	23,782		$	551
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	The fair values of the company’s derivative instruments were as follows (in thousands):
		September 30, 2013						December 31, 2012
		Assets			Liabilities			Assets			Liabilities
	Derivatives designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	$	626		$	681		$	375		$	915
	Interest rate swap contracts	—			22			—			316
	Derivatives not designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	685			68			687			142
	Total derivatives	$	1,311		$	771		$	1,062		$	1,373
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	'
	The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands):
	Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain  (Loss)			Amount of Gain (Loss)
	relationships	(Loss) Recognized in OCI on Derivatives			Reclassified from			Recognized in Income on
		(Effective Portion)			Accumulated  OCI into			Derivatives  (Ineffective Portion
					Income (Effective			and Amount Excluded from
					Portion)			Effectiveness Testing)
	Three months ended September 30, 2013
	Foreign currency forward exchange contracts	$	(207	)	$	83		$	2
	Interest rate swap contracts	33			(13		)	—
		$	(174	)	$	70		$	2
	Nine months ended September 30, 2013
	Foreign currency forward exchange contracts	$	505		$	(20	)	$	37
	Interest rate swap contracts	433			(139		)	—
		$	938		$	(159	)	$	37
	Three months ended September 30, 2012
	Foreign currency forward exchange contracts	$	(2,522	)	$	1,241		$	(38	)
	Interest rate swap contracts	(3		)	—			—
		$	(2,525	)	$	1,241		$	(38	)
	Nine months ended September 30, 2012
	Foreign currency forward exchange contracts	$	(2,956	)	$	2,706		$	(9	)
	Interest rate swap contracts	(99		)	—			—
		$	(3,055	)	$	2,706		$	(9	)
	Derivatives not designated as hedging							Amount of Gain (Loss)
	instruments under ASC 815							Recognized in Income on Derivatives
	Three months ended September 30, 2013
	Foreign currency forward exchange contracts							$	361
	Nine months ended September 30, 2013
	Foreign currency forward exchange contracts							$	617
	Three months ended September 30, 2012
	Foreign currency forward exchange contracts							$	569
	Nine months ended September 30, 2012
	Foreign currency forward exchange contracts							$	551

Fair_Values_of_Financial_Instr

Fair Values of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands).
					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	30-Sep-13
	Forward Exchange Contracts—net	$	562		—			$	562			—
	Interest Rate Swap Agreements—net	(22		)	—			(22		)		—
	December 31, 2012:
	Forward Exchange Contracts—net	$	5		—			$	5			—
	Interest Rate Swap Agreements—net	(316		)	—			(316		)		—
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The carrying values and fair values of the company’s financial instruments are as follows (in thousands):
		September 30, 2013							December 31, 2012
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	32,625		$	32,625			$	38,791			$	38,791
	Other investments	1,190			1,190				1,171				1,171
	Installment receivables, net of reserves	2,236			2,236				2,594				2,594
	Long-term debt (including current maturities of long-term debt)	(56,069		)	(56,115		)		(234,802		)		(234,072		)
	Forward contracts in Other Current Assets	1,311			1,311				1,062				1,062
	Forward contracts in Accrued Expenses	(749		)	(749		)		(1,057		)		(1,057		)
	Interest rate swap agreements in Accrued Expenses	(22		)	(22		)		(316		)		(316		)

Business_Segments_Tables

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The information by segment is as follows (in thousands):
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2013			2012			2013			2012
	Revenues from external customers
	North America/HME	$	151,052		$	170,701		$	462,261		$	527,103
	Institutional Products Group	28,083			33,557			87,135			95,726
	Europe	150,265			141,705			429,650			401,721
	Asia/Pacific	11,776			15,555			38,327			53,217
	Consolidated	$	341,176		$	361,518		$	1,017,373		$	1,077,767
	Intersegment revenues
	North America/HME	$	20,501		$	24,813		$	59,735		$	81,985
	Institutional Products Group	1,254			1,941			4,243			5,471
	Europe	1,890			3,239			6,156			8,448
	Asia/Pacific	6,411			7,737			19,417			27,177
	Consolidated	$	30,056		$	37,730		$	89,551		$	123,081
	Restructuring charges before income taxes
	North America/HME	$	1,210		$	352		$	4,837		$	2,214
	Institutional Products Group	36			—			237			35
	Europe	542			481			722			772
	Asia/Pacific	96			342			1,202			721
	Consolidated	$	1,884		$	1,175		$	6,998		$	3,742
	Earnings (loss) before income taxes
	North America/HME	$	(10,191	)	$	(28	)	$	(33,593	)	$	8,086
	Institutional Products Group	1,009			579			1,955			4,820
	Europe	13,136			10,218			27,344			23,504
	Asia/Pacific	(2,233		)	(2,301		)	(9,871		)	(4,139		)
	All Other (1)	(6,354		)	(5,460		)	(17,515		)	(17,411		)
	Consolidated	$	(4,633	)	$	3,008		$	(31,680	)	$	14,860
	________________________
	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the “All Other” earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees.

Supplemental_Guarantor_Informa1

Supplemental Guarantor Information Supplemental Guarantor Information (Tables)	9 Months Ended
	Sep. 30, 2013
Supplemental Guarantor Information [Abstract]	'
Schedule of Guarantor Obligations [Table Text Block]	'
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Nine month period ended September 30, 2012	(in thousands)
	Net sales	$	275,742		$	355,378		$	540,535		$	(93,888	)	$	1,077,767
	Cost of products sold	211,115			256,854			371,855			(93,455		)	746,369
	Gross Profit	64,627			98,524			168,680			(433		)	331,398
	Selling, general and administrative expenses	99,736			64,452			138,207			4,360			306,755
	Charge related to restructuring activities	2,085			39			1,618			—			3,742
	Loss on debt extinguishment including debt finance charges and associated fees	312			—			—			—			312
	Income (loss) from equity investee	45,175			1,954			391			(47,520		)	—
	Interest expense (income)—net	(3,041		)	6,396			2,374			—			5,729
	Earnings (Loss) from Continuing Operations before Income Taxes	10,710			29,591			26,872			(52,313		)	14,860
	Income taxes (benefit)	1,590			(5,164		)	18,060			—			14,486
	Net Earnings (Loss) from Continuing Operations	9,120			34,755			8,812			(52,313		)	374
	Net Earnings from Discontinued Operations	—			8,746			—			—			8,746
	Net Earnings (loss)	$	9,120		$	43,501		$	8,812		$	(52,313	)	$	9,120
	Other Comprehensive Income (Loss), Net of Tax	(24,673		)	3,179			(27,878		)	24,699			(24,673		)
	Comprehensive Income (Loss)	$	(15,553	)	$	46,680		$	(19,066	)	$	(27,614	)	$	(15,553	)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Nine month period ended September 30, 2013
	Net sales	$	186,453		$	364,005		$	535,805		$	(68,890	)	$	1,017,373
	Cost of products sold	159,884			264,501			378,287			(69,264		)	733,408
	Gross Profit	26,569			99,504			157,518			374			283,965
	Selling, general and administrative expenses	99,338			72,370			131,640			2,694			306,042
	Charge related to restructuring activities	5,078			49			1,871			—			6,998
	Asset write-downs to intangibles and investments	—			167			—			—			167
	Income (loss) from equity investee	105,501			21,472			(93		)	(126,880		)	—
	Interest expense (income)—net	(1,418		)	3,141			715			—			2,438
	Earnings (Loss) from Continuing Operations before Income Taxes	29,072			45,249			23,199			(129,200		)	(31,680		)
	Income taxes (benefit)	(9,749		)	—			13,649			—			3,900
	Net Earnings (Loss) from Continuing Operations	38,821			45,249			9,550			(129,200		)	(35,580		)
	Net Earnings from Discontinued Operations	—			74,401			—			—			74,401
	Net Earnings (loss)	$	38,821		$	119,650		$	9,550		$	(129,200	)	$	38,821
	Other Comprehensive Income (Loss), Net of Tax	1,845			(415		)	2,228			(1,813		)	1,845
	Comprehensive Income (Loss)	$	40,666		$	119,235		$	11,778		$	(131,013	)	$	40,666
	CONSOLIDATING CONDENSED BALANCE SHEETS
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	December 31, 2012	(in thousands)
	Assets
	Current Assets
	Cash and cash equivalents	$	5,774		$	1,018		$	31,999		$	—		$	38,791
	Trade receivables, net	71,622			37,223			89,946			—			198,791
	Installment receivables, net	—			829			1,359			—			2,188
	Inventories, net	40,278			31,455			114,169			(2,656		)	183,246
	Intercompany advances, net	4,077			763			64,570			(69,410		)	—
	Other current assets	12,727			473			34,606			(6,030		)	41,776
	Assets held for sale - current	—			103,157			—			—			103,157
	Total Current Assets	134,478			174,918			336,649			(78,096		)	567,949
	Investment in subsidiaries	1,536,898			523,176			6,888			(2,066,962		)	—
	Intercompany advances, net	863,973			1,468,405			173,903			(2,506,281		)	—
	Other Assets	41,006			314			942			—			42,262
	Other Intangibles	663			22,211			48,778			—			71,652
	Property and Equipment, net	39,911			19,957			58,363			—			118,231
	Goodwill	—			32,937			429,263			—			462,200
	Total Assets	$	2,616,929		$	2,241,918		$	1,054,786		$	(4,651,339	)	$	1,262,294
	Liabilities and Shareholders’ Equity
	Current Liabilities
	Accounts payable	$	63,812		$	9,465		$	59,771		$	—		$	133,048
Accrued expenses	36,716			18,155			86,348			(6,030		)	135,189
Accrued income taxes	1,545			—			1,168			—			2,713
Intercompany advances, net	61,368			2,369			5,673			(69,410		)	—
Short-term debt and current maturities of long-term obligations	4,552			7			868			—			5,427
Liabilities held for sale - current	—			23,358			—			—			23,358
Total Current Liabilities	167,993			53,354			153,828			(75,440		)	299,735
Long-Term Debt	223,014			143			6,218			—			229,375
Other Long-Term Obligations	52,957			—			59,238			—			112,195
Intercompany advances, net	1,551,976			863,585			90,720			(2,506,281		)	—
Total Shareholders’ Equity	620,989			1,324,836			744,782			(2,069,618		)	620,989
Total Liabilities and Shareholders’ Equity	$	2,616,929		$	2,241,918		$	1,054,786		$	(4,651,339	)	$	1,262,294
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Three month period ended September 30, 2012	(in thousands)
Net sales	$	90,406		$	116,339		$	183,801		$	(29,028	)	$	361,518
Cost of products sold	70,600			83,685			126,852			(29,031		)	252,106
Gross Profit	19,806			32,654			56,949			3			109,412
Selling, general and administrative expenses	33,712			20,356			45,492			3,721			103,281
Charge related to restructuring activities	334			18			823			—			1,175
Loss on debt extinguishment including debt finance charges and associated fees	—			—			—			—			—
Income (loss) from equity investee	17,302			(4,264		)	228			(13,266		)	—
Interest expense (income)—net	(1,024		)	2,201			771			—			1,948
Earnings (Loss) from Continuing Operations before Income Taxes	4,086			5,815			10,091			(16,984		)	3,008
Income taxes (benefit)	1,222			(3,028		)	4,251			—			2,445
Net Earnings (Loss) from Continuing Operations	2,864			8,843			5,840			(16,984		)	563
Net Earnings from Discontinued Operations	—			2,301			—			—			2,301
Net Earnings (loss)	$	2,864		$	11,144		$	5,840		$	(16,984	)	$	2,864
Other Comprehensive Income (Loss), Net of Tax	14,518			3,164			11,412			(14,576		)	14,518
Comprehensive Income (Loss)	$	17,382		$	14,308		$	17,252		$	(31,560	)	$	17,382
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Three month period ended September 30, 2013	(in thousands)
Net sales	$	60,641		$	119,548		$	184,299		$	(23,312	)	$	341,176
Cost of products sold	52,454			86,978			128,232			(23,312		)	244,352
Gross Profit	8,187			32,570			56,067			—			96,824
Selling, general and administrative expenses	29,046			25,363			44,310			—			98,719
Charge related to restructuring activities	1,597			36			251			—			1,884
Asset write-downs to intangibles and investments	—			167			—			—			167
Income (loss) from equity investee	32,513			8,935			22			(41,470		)	—
Interest expense (income)—net	(603		)	1,213			77			—			687
Earnings (Loss) from Continuing Operations before Income Taxes	10,660			14,726			11,451			(41,470		)	(4,633		)
Income taxes (benefit)	(5,442		)	—			6,192			—			750
Net Earnings (Loss) from Continuing Operations	16,102			14,726			5,259			(41,470		)	(5,383		)
Net Earnings from Discontinued Operations	—			21,485			—			—			21,485
Net Earnings (loss)	$	16,102		$	36,211		$	5,259		$	(41,470	)	$	16,102
Other Comprehensive Income (Loss), Net of Tax	9,874			220			10,135			(10,355		)	9,874
Comprehensive Income (Loss)	$	25,976		$	36,431		$	15,394		$	(51,825	)	$	25,976
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
September 30, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	3,148		$	—		$	29,477		$	—		$	32,625
Trade receivables, net	69,633			29,453			92,378			—			191,464
Installment receivables, net	—			569			991			—			1,560
Inventories, net	37,797			27,784			104,970			(3,183		)	167,368
Intercompany advances, net	5,055			664			43,145			(48,864		)	—
Other current assets	6,371			570			34,129			(7,240		)	33,830
Total Current Assets	122,004			59,040			305,090			(59,287		)	426,847
Investment in subsidiaries	1,433,252			440,197			—			(1,873,449		)	—
Intercompany advances, net	937,116			1,592,785			178,180			(2,708,081		)	—
Other Assets	38,961			463			903			—			40,327
Other Intangibles	553			19,139			45,413			—			65,105
Property and Equipment, net	36,783			18,621			52,987			—			108,391
Goodwill	—			16,660			434,067			—			450,727
Total Assets	$	2,568,669		$	2,146,905		$	1,016,640		$	(4,640,817	)	$	1,091,397
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	50,462		$	8,237		$	58,985		$	—		$	117,684
Accrued expenses	30,864			17,737			89,118			(7,240		)	130,479
Accrued income taxes	5,540			—			1,661			—			7,201
Intercompany advances, net	41,889			1,481			5,494			(48,864		)	—
Short-term debt and current maturities of long-term obligations	556			7			731			—			1,294
Total Current Liabilities	129,311			27,462			155,989			(56,104		)	256,658
Long-Term Debt	22,476			82			32,217			—			54,775
Other Long-Term Obligations	54,176			—			60,597			—			114,773
Intercompany advances, net	1,707,515			936,722			63,844			(2,708,081		)	—
Total Shareholders’ Equity	655,191			1,182,639			703,993			(1,876,632		)	665,191
Total Liabilities and Shareholders’ Equity	$	2,568,669		$	2,146,905		$	1,016,640		$	(4,640,817	)	$	1,091,397
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Nine month period ended September 30, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	35,179		$	(81,077	)	$	(20,736	)	$	65,389		$	(1,245	)
Investing Activities
Purchases of property and equipment	(3,234		)	(3,611		)	(4,241		)	—			(11,086		)
Proceeds from sale of property and equipment	—			11			845			—			856
Proceeds from sale of business	—			187,552			—			—			187,552
Other long-term assets	783			—			166			—			949
Other	171,353			(103,417		)	—			(68,083		)	(147		)
Net Cash Provided (Used) for Investing Activities	168,902			80,535			(3,230		)	(68,083		)	178,124
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	226,189			—			23,935			—			250,124
Payments on revolving lines of credit and long-term borrowings	(431,709		)	(476		)	—			—			(432,185		)
Payment of dividends	(1,187		)	—			(2,694		)	2,694			(1,187		)
Net Cash Provided (Used) by Financing Activities	(206,707		)	(476		)	21,241			2,694			(183,248		)
Effect of exchange rate changes on cash	—			—			203			—			203
Decrease in cash and cash equivalents	(2,626		)	(1,018		)	(2,522		)	—			(6,166		)
Cash and cash equivalents at beginning of year	5,774			1,018			31,999			—			38,791
Cash and cash equivalents at end of period	$	3,148		$	—		$	29,477		$	—		$	32,625
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Nine month period ended September 30, 2012	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	18,260		$	5,405		$	7,527		$	(4,370	)	$	26,822
Investing Activities
Purchases of property and equipment	(1,353		)	(7,854		)	(5,568		)	—			(14,775		)
Proceeds from sale of property and equipment	18			14			65			—			97
Other long-term assets	(214		)	—			623			—			409
Other	(158		)	(117		)	56			—			(219		)
Net Cash Used for Investing Activities	(1,707		)	(7,957		)	(4,824		)	—			(14,488		)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	252,590			3,113			—			—			255,703
Payments on revolving lines of credit and long-term borrowings	(266,182		)	—			(539		)	—			(266,721		)
Payment of financing costs	(1		)	—			—			—			(1		)
Payment of dividends	(1,183		)	—			(4,370		)	4,370			(1,183		)
Net Cash Provided (Used) by Financing Activities	(14,776		)	3,113			(4,909		)	4,370			(12,202		)
Effect of exchange rate changes on cash	—			—			226			—			226
Increase (Decrease) in cash and cash equivalents	1,777			561			(1,980		)	—			358
Cash and cash equivalents at beginning of year	3,642			2,104			29,178			—			34,924
Cash and cash equivalents at end of period	$	5,419		$	2,665		$	27,198		$	—		$	35,282

Accounting_Policies_Details

Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Significant Accounting Policies [Line Items]	'	'	'	'
Share-based Compensation	$2,147	$2,208	$4,721	$5,198

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jan. 18, 2013

Dec. 21, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Aug. 06, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

ISG [Member]

ISG [Member]

ISG [Member]

ISG [Member]

ISG [Member]

ISG [Member]

ISG [Member]

Champion [Member]

Champion [Member]

Champion [Member]

Champion [Member]

Champion [Member]

Champion [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement to Sell Operations Date

'

'

'

'

21-Dec-12

'

'

'

'

'

'

'

'

'

'

'

Disposal Date

'

'

'

18-Jan-13

'

'

'

'

'

'

6-Aug-13

'

'

'

'

'

Proceeds from Divestiture of Businesses

'

'

'

'

'

'

'

$150,800,000

'

'

'

'

'

$45,000,000

'

'

Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal

-82,163,000

0

'

'

'

'

'

59,402,000

'

'

'

'

'

22,761,000

'

'

Disposal Group, Expenses Related to Sale of Business

'

'

'

'

'

'

'

5,350,000

'

'

'

'

'

2,130,000

'

'

Disposal Group, Expenses Related to Sale of Business, cash paid

'

'

'

'

'

'

'

3,392,000

'

'

'

'

'

1,367,000

'

'

Disposal Group Assets and Liabilities Sold [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trade receivables, net

'

'

'

'

'

'

'

'

'

44,196,000

3,030,000

'

'

'

'

2,375,000

Inventories, net

'

'

'

'

'

'

'

'

'

25,165,000

1,689,000

'

'

'

'

1,617,000

Other current assets

'

'

'

'

'

'

'

'

'

9,355,000

92,000

'

'

'

'

21,000

Property and Equipment, net

'

'

'

'

'

'

'

'

'

1,368,000

309,000

'

'

'

'

237,000

Goodwill

'

'

'

'

'

'

'

'

'

23,073,000

16,277,000

'

'

'

'

16,277,000

Assets Held-for-sale, Current

0

'

103,157,000

'

'

'

'

'

'

103,157,000

'

'

'

'

'

'

Assets Sold

'

'

'

'

'

'

'

'

'

'

21,397,000

'

'

'

'

20,527,000

Disposal Group, Including Discontinued Operation, Accounts Payable

'

'

'

'

'

'

'

'

'

17,692,000

936,000

'

'

'

'

475,000

Disposal Group, Including Discontinued Operation, Accrued Liabilities

'

'

'

'

'

'

'

'

'

4,602,000

352,000

'

'

'

'

318,000

Net Sales from Discontinued Operations

'

'

'

'

'

0

85,763,000

18,498,000

246,433,000

'

'

2,643,000

5,700,000

15,857,000

17,271,000

'

Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax

'

'

'

'

'

0

3,894,000

402,000

10,703,000

'

'

484,000

1,037,000

3,156,000

3,307,000

'

Liabilities Sold

'

'

'

'

'

'

'

'

'

'

1,288,000

'

'

'

'

993,000

Interest Expense Allocation from Continuing to Discontinuing Operations

'

'

'

'

'

'

'

'

'

'

'

78,000

198,000

449,000

594,000

'

Disposal Group, Including Discontinued Operation, Accrued Income Taxes Payable

'

'

'

'

'

'

'

'

'

1,064,000

0

'

'

'

'

200,000

Liabilities of Assets Held-for-sale

0

'

23,358,000

'

'

'

'

'

'

23,358,000

'

'

'

'

'

'

Discontinued Operations, Allocated Goodwill

'

'

'

'

'

'

'

'

'

'

$16,205,000

'

'

'

'

'

Receivables_Narrative_Details

Receivables Narrative (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for Doubtful Accounts Receivable	$20,836,000	$22,213,000
Number of Missed Payments before Delinquent	3	'
Typical Financing Period	'12 months	'
Credit amount requiring additional analysis	250,000	'
Average Period of Adjudication	'18 months	'
Installment receivable purchased from DLL	$2,415,000	'

Receivables_Details

Receivables (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Total Installment Receivables	$5,948	$6,488	'
Installment Receivables, Net of Unearned Interest	5,878	6,417	'
Allowance for doubtful accounts	-3,642	-3,823	'
Installment receivables, net	1,560	2,188	'
Installment receivables, net, long-term	676	406	'
Installment Receivables [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Installment Receivables, Current	3,554	4,982	'
Installment Receivables, Long-Term	2,394	1,506	'
Total Installment Receivables	5,948	6,488	'
Unearned Interest, Current	-70	-71	'
Unearned Interest, Noncurrent	0	0	'
Total Unearned Interest	-70	-71	'
Installment Receivables Net of Unearned Interest Current	3,484	4,911	'
Installment Receivables Net of Unearned Interest Noncurrent	2,394	1,506	'
Installment Receivables, Net of Unearned Interest	5,878	6,417	'
Allowance for doubtful accounts, current	-1,924	-2,723	'
Allowance for doubtful accounts, long-term	-1,718	-1,100	'
Allowance for doubtful accounts	-3,642	-3,823	-4,273
Installment receivables, net	1,560	2,188	'
Installment receivables, net, long-term	676	406	'
Installment receivables, net	$2,236	$2,594	'

Receivables_Rollforward_of_All

Receivables Rollforward of Allowance for Doubtful Accounts (Details) (USD $)	9 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
			Installment Receivables [Member]	Installment Receivables [Member]
Allowance for Doubtful Accounts [Roll Forward]	'	'	'	'
Balance as of January 1	$3,823	'	$3,823	$4,273
Current period provision	3,160	4,252	943	458
Direct write-offs charged against the allowance	'	'	-1,124	-908
Balance as of December 31	$3,642	'	$3,642	$3,823

Receivables_Installment_Receiv

Receivables Installment Receivables by Class (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	$5,948	$6,488
Unpaid Principal Balance	5,878	6,417
Related Allowance for Doubtful Accounts	3,642	3,823
Interest Income Recognized	76	120
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,438	1,980
Unpaid Principal Balance	1,368	1,909
Related Allowance for Doubtful Accounts	165	458
Interest Income Recognized	76	120
Impaired Installment Receivables with Related Allowance [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	4,675	4,966
Unpaid Principal Balance	4,675	4,966
Related Allowance for Doubtful Accounts	3,642	3,823
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] | U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	4,510	4,508
Unpaid Principal Balance	4,510	4,508
Related Allowance for Doubtful Accounts	3,477	3,365
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] | CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	165	458
Unpaid Principal Balance	165	458
Related Allowance for Doubtful Accounts	165	458
Interest Income Recognized	0	0
Installment Receivables [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,273	1,522
Unpaid Principal Balance	1,203	1,451
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	76	120
Installment Receivables [Member] | CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,273	1,522
Unpaid Principal Balance	1,203	1,451
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	$76	$120

Receivables_Aging_of_Installme

Receivables Aging of Installment Receivables (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	$1,218	$1,467
0-30 Days Past Due	9	43
31-60 Days Past Due	6	2
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	4,715	4,976
Total Installment Receivables Past Due	5,948	6,488
U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	0	0
0-30 Days Past Due	0	0
31-60 Days Past Due	0	0
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	4,510	4,508
Total Installment Receivables Past Due	4,510	4,508
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	1,218	1,467
0-30 Days Past Due	9	43
31-60 Days Past Due	6	2
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	205	468
Total Installment Receivables Past Due	$1,438	$1,980

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Finished goods	$90,422	$94,675
Raw materials	61,642	71,596
Work in process	15,304	16,975
Inventory, Net	$167,368	$183,246

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other Current Assets [Abstract]	'	'
Value Added Tax Receivable, Current	$15,004	$18,002
Income Taxes Receivable, Current	3,457	6,192
Derivative Assets	1,311	1,062
Prepaid Insurance	300	2,241
Prepaid Expense and Other Assets, Current	13,758	14,279
Other current assets	$33,830	$41,776

Other_LongTerm_Assets_Details

Other Long-Term Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Text Block [Abstract]	'	'
Cash Surrender Value of Life Insurance	$35,772	$36,375
Deferred Finance Costs, Noncurrent, Net	1,356	2,728
Long-term Investments	1,190	1,171
Installment receivables, net, long-term	676	406
Prepaid Expense and Other Assets, Noncurrent	1,333	1,582
Other Assets	$40,327	$42,262

Property_And_Equipment_Details

Property And Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$475,053	$479,931
Less allowance for depreciation	-366,662	-361,700
Property and Equipment, net	108,391	118,231
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	356,935	356,512
Land, Buildings and Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	90,234	95,047
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	12,998	13,397
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$14,886	$14,975

Goodwill_Goodwill_Details

Goodwill Goodwill (Details) (Champion [Member], USD $)	Aug. 06, 2013	Dec. 31, 2012
Champion [Member]	'	'
Goodwill [Line Items]	'	'
Goodwill	$16,277,000	$16,277,000

Other_Intangibles_Narrative_De

Other Intangibles Narrative (Details) (USD $)	9 Months Ended			9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
		Trademarks [Member]	Trademarks [Member]	NA/HME [Member]	Minimum [Member]	Maximum [Member]
				Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Indefinite-lived Intangible Assets	'	$31,299,000	$31,280,000	'	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'	'3 years	'17 years
Finite Lived Intangible Assets, Useful Life Minimum for Majority of Assets	'10 years	'	'	'	'	'
Finite-Lived Intangible Assets, Average Useful Life	'13 years	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	6,937,000	'	'	'	'	'
Impairment of Intangible Assets, Finite-lived	'	'	'	$167,000	'	'

Other_Intangibles_Details

Other Intangibles (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	$147,379,000	$151,345,000
Finite-Lived Intangible Assets, Accumulated Amortization	82,274,000	79,693,000
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	91,344,000	93,572,000
Finite-Lived Intangible Assets, Accumulated Amortization	61,888,000	58,447,000
Licensing Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	1,428,000	3,212,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,428,000	3,212,000
Developed Technology Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	9,712,000	9,650,000
Finite-Lived Intangible Assets, Accumulated Amortization	6,098,000	5,588,000
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	6,115,000	6,060,000
Finite-Lived Intangible Assets, Accumulated Amortization	5,472,000	5,234,000
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	7,481,000	7,571,000
Finite-Lived Intangible Assets, Accumulated Amortization	7,388,000	7,212,000
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-lived Intangible Assets	$31,299,000	$31,280,000

Other_Intangibles_FiniteLived_

Other Intangibles Finite-Lived Intangible Asset Future Amortization Expense (Details) (USD $)	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'
Future Amortization Expense, Entire Fiscal Year	$9,182,000
Future Amortization Expense, Year One	8,670,000
Future Amortization Expense, Year Two	7,174,000
Future Amortization Expense, Year Three	5,796,000
Future Amortization Expense, Year Four	2,290,000
Future Amortization Expense, Year Five	$2,290,000

Current_Liabilities_Details

Current Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued Salaries, Current	$37,480	$41,813
Accrual for Taxes Other than Income Taxes, Current	23,225	24,600
Product Warranty Accrual, Current	25,020	21,451
Accrued Freight Expense, Current	7,806	7,853
Accrued Professional Fees, Current	7,355	7,595
Product Liability, Current	3,572	3,323
Accrued Rebates, Current	2,136	3,635
Accrued Insurance, Current	2,726	2,674
Interest Payable, Current	921	1,268
Derivative Liabilities, Current	771	1,373
Other Employee Related Liabilities, Current	3,481	5,211
Other Accrued Liabilities, Current	15,986	14,393
Accrued expenses	$130,479	$135,189

Warrany_Costs_Warranty_Schedul

Warrany Costs Warranty Schedule (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities, Current [Abstract]	'
Loss Contingency Accrual, at Carrying Value	$3,800,000
Balance as of January 1	21,451,000
Warranties provided during the period	7,843,000
Settlements made during the period	-8,741,000
Changes in liability for pre-existing warranties during the period, including expirations	4,467,000
Balance as of June 30	$25,020,000

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term Debt	$56,069	$234,802
Long-term Debt, Current Maturities	-1,294	-5,427
Long-term Debt, Excluding Current Maturities	54,775	229,375
Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt	38,968	217,494
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt	10,476	10,009
Notes Payable, Other Payables [Member] | Other Notes and Lease Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt	$6,625	$7,299

LongTerm_Debt_Line_of_Credit_D

Long-Term Debt Line of Credit (Details) (USD $)	0 Months Ended	9 Months Ended
	30-May-13	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	28-May-13	Sep. 30, 2013	28-May-13
			Convertible Subordinated Debt [Member]	Maximum [Member]	Maximum [Member]	Minimum [Member]	Minimum [Member]
			Convertible Senior Subordinated Debentures February 2027 [Member]	Line of Credit [Member]	Line of Credit [Member]	Line of Credit [Member]	Line of Credit [Member]
				Senior Secured Revolving Credit Facility October 2015 [Member]	Senior Secured Revolving Credit Facility October 2015 [Member]	Senior Secured Revolving Credit Facility October 2015 [Member]	Senior Secured Revolving Credit Facility October 2015 [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Debt Amendment Date	30-May-13	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$400,000,000	$250,000,000	'	'	'	'	'
Line of Credit Facility, Current Borrowing Capacity	'	200,000,000	'	'	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	'	'	'	4	3.5	'	'
Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense	'	'	'	'	'	3	3.5
Future One-Time Cash Restructuring Charges Added Back to EBITDA	'	15,000,000	'	'	'	'	'
Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt	25	'	'	'	'	'	'
Increase in Basis Points for Commitment Fees for New Debt	10	'	'	'	'	'	'
Payments of Debt Issuance Costs	'	436,000	'	'	'	'	'
Write off of Deferred Debt Issuance Cost	'	'	$1,216,000	'	'	'	'

LongTerm_Debt_Convertible_Debt

Long-Term Debt Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Feb. 17, 2007
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt Instrument, Unamortized Discount	($2,874,000)	($3,341,000)	'
Principal Amount	'	'	$135,000,000
Interest Rate	4.13%	'	'

LongTerm_Debt_Interest_Rate_Sw

Long-Term Debt Interest Rate Swaps (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Derivative [Line Items]	'	'
Long-term Debt, Weighted Average Interest Rate	2.45%	2.21%
Interest Rate Derivative, April 2014, .54% [Member] | Interest Rate Swap [Member]	'	'
Derivative [Line Items]	'	'
Notional Amount of Interest Rate Derivatives	12,000,000	'
Derivative, Fixed Interest Rate on LIBOR Component	0.54%	'
Derivative, Effective Aggregate Interest Rate	3.04%	'

LongTerm_Debt_Components_of_Co

Long-Term Debt Components of Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount of liability component	$13,350	$13,350
Debt Instrument, Unamortized Discount	-2,874	-3,341
Convertible Debt	$10,476	$10,009

Shareholders_Equity_Transactio2

Shareholders' Equity Transactions Narrative (Details) (USD $)	0 Months Ended			9 Months Ended
	21-May-13	16-May-13	Mar. 27, 2013	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	4,460,337	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'	'	'	756,700
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	21-May-13	'	'	'
Annual Shareholder Meeting Date	'	16-May-13	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Adoption date	'	'	27-Mar-13	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	$13,264,000
Restricted Stock [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	'	'	'	362,323
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	4,169,000
Allocated Share-based Compensation Expense	'	'	'	$1,568,000
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'4 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	4,460,337	[1]
[1]	*Options available for grant as of SeptemberB 30, 2013 reduced by net restricted stock award activity of 793,351.

Shareholders_Equity_Transactio3

Shareholders' Equity Transactions Options Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013		16-May-13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'
Options outstanding at beginning of period	4,664,634		'
Granted	756,700		'
Excercised	0		'
Canceled	-792,584		'
Options outstanding at end of period	4,628,750		'
Options outstanding at beginning of period Weighted Average Exercise Price	$26.21		'
Granted Weighted Average Exercise Price	$14.47		'
Excercised Weighted Average Exercise Price	$0		'
Canceled Weighted Average Exercise Price	$28.74		'
Options outstanding at end of period Weighted Average Exercise Price	$23.86		'
Options exercise price range at end of period, Lower Limit	$12.42		'
Options exercise price range at end of period, Upper Limit	$47.80		'
Options exercisable at end of period	3,070,364		'
Options available for grant at end of period	'		4,460,337
Stock Options [Member]	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'
Options available for grant at end of period	4,460,337	[1]	'
Restricted Stock [Member]	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	793,351		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	114,700		'
[1]	*Options available for grant as of SeptemberB 30, 2013 reduced by net restricted stock award activity of 793,351.

Shareholders_Equity_Transactio4

Shareholders' Equity Transactions Stock Options Outstanding by Exercise Price (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'10 years	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	4,628,750	'
Weighted Average Remaining Contractual Life	'6 years 0 months 13 days	'
Weighted Average Exercise Price	$23.86	$26.21
Number Exercisable At end of period	3,070,364	'
Weighted Average Exercise Price	$27.57	'
Range of Exercise Price 12.42 to 15.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$15	'
Number Outstanding at end of period	1,354,435	'
Weighted Average Remaining Contractual Life	'9 years 2 months 13 days	'
Weighted Average Exercise Price	$13.95	'
Number Exercisable At end of period	166,045	'
Weighted Average Exercise Price	$13.38	'
Range of Exercise Price 15.01 to 25.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$15.01	'
Range of Exercise Price, Upper Limit	$25	'
Number Outstanding at end of period	1,613,291	'
Weighted Average Remaining Contractual Life	'5 years 7 months 13 days	'
Weighted Average Exercise Price	$22.51	'
Number Exercisable At end of period	1,364,559	'
Weighted Average Exercise Price	$22.21	'
Range of Exercise Price 25.01 to 35.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$25.01	'
Range of Exercise Price, Upper Limit	$35	'
Number Outstanding at end of period	950,109	'
Weighted Average Remaining Contractual Life	'5 years 8 months 13 days	'
Weighted Average Exercise Price	$25.81	'
Number Exercisable At end of period	828,846	'
Weighted Average Exercise Price	$25.85	'
Range of Exercise Price 35.01 to 47.80 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$35.01	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	710,915	'
Weighted Average Remaining Contractual Life	'1 year 4 months 13 days	'
Weighted Average Exercise Price	$43.21	'
Number Exercisable At end of period	710,914	'
Weighted Average Exercise Price	$43.21	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	$104,714	'	$112,743	'
OCI before reclassifications	9,858	'	1,954	'
Amount reclassified from accumulated OCI	16	'	-109	'
Net current-period OCI	9,874	14,518	1,845	-24,673
Ending Balance	114,588	'	114,588	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Cost of Products Sold	244,352	252,106	733,408	746,369
Interest Expense	-687	-1,948	-2,438	-5,729
Tax	-750	-2,445	-3,900	-14,486
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	117,817	'	117,465	'
OCI before reclassifications	17,852	'	18,204	'
Amount reclassified from accumulated OCI	0	'	0	'
Net current-period OCI	17,852	'	18,204	'
Ending Balance	135,669	'	135,669	'
Accumulated Long-Term Notes Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	-6,743	'	2,845	'
OCI before reclassifications	-8,062	'	-17,650	'
Amount reclassified from accumulated OCI	0	'	0	'
Net current-period OCI	-8,062	'	-17,650	'
Ending Balance	-14,805	'	-14,805	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	-6,419	'	-6,785	'
OCI before reclassifications	265	'	750	'
Amount reclassified from accumulated OCI	-62	'	-181	'
Net current-period OCI	203	'	569	'
Ending Balance	-6,216	'	-6,216	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Service and interest costs	-64	'	-187	'
Tax	2	'	6	'
Total after tax	-62	'	-181	'
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	59	'	-782	'
OCI before reclassifications	-197	'	650	'
Amount reclassified from accumulated OCI	78	'	72	'
Net current-period OCI	-119	'	722	'
Ending Balance	-60	'	-60	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Total before tax	87	'	96	'
Tax	-9	'	-24	'
Total after tax	78	'	72	'
Foreign Exchange Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Net Sales	-54	'	-496	'
Commodity Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Cost of Products Sold	128	'	453	'
Interest Rate Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Interest Expense	$13	'	$139	'

Charges_Related_To_Restructuri2

Charges Related To Restructuring Activities (Details) (USD $)	3 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	$5,902,000	$5,493,000	$6,993,000	$6,993,000	$4,979,000	$0
Restructuring Charges including Inventory Markdowns	1,884,000	2,592,000	2,522,000	6,998,000	11,395,000	10,534,000
Restructuring Reserve, Settled with Cash	-3,625,000	-2,183,000	-4,022,000	-9,830,000	-9,381,000	-5,555,000
Restructuring Reserve, Ending Balance	4,161,000	5,902,000	5,493,000	4,161,000	6,993,000	4,979,000
Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	4,920,000	4,546,000	5,211,000	5,211,000	4,905,000	0
Restructuring Charges including Inventory Markdowns	1,434,000	2,506,000	2,436,000	'	6,775,000	8,352,000
Restructuring Reserve, Settled with Cash	-2,873,000	-2,132,000	-3,101,000	'	-6,469,000	-3,447,000
Restructuring Reserve, Ending Balance	3,481,000	4,920,000	4,546,000	3,481,000	5,211,000	4,905,000
Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	151,000	151,000	0	0
Restructuring Charges including Inventory Markdowns	0	0	0	'	491,000	277,000
Restructuring Reserve, Settled with Cash	0	0	-151,000	'	-340,000	-277,000
Restructuring Reserve, Ending Balance	0	0	0	0	151,000	0
Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	982,000	945,000	1,625,000	1,625,000	74,000	0
Restructuring Charges including Inventory Markdowns	292,000	86,000	86,000	'	1,725,000	1,788,000
Restructuring Reserve, Settled with Cash	-642,000	-49,000	-766,000	'	-174,000	-1,714,000
Restructuring Reserve, Ending Balance	632,000	982,000	945,000	632,000	1,625,000	74,000
Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	2,000	6,000	6,000	0	0
Restructuring Charges including Inventory Markdowns	158,000	0	0	'	2,404,000	117,000
Restructuring Reserve, Settled with Cash	-110,000	-2,000	-4,000	'	-2,398,000	-117,000
Restructuring Reserve, Ending Balance	48,000	0	2,000	48,000	6,000	0
NA/HME [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	3,574,000	3,421,000	3,747,000	3,747,000	3,092,000	'
Restructuring Charges including Inventory Markdowns	1,210,000	1,948,000	1,679,000	'	4,247,000	4,759,000
Restructuring Reserve, Settled with Cash	-2,014,000	-1,795,000	-2,005,000	'	-3,592,000	-1,667,000
Restructuring Reserve, Ending Balance	2,770,000	3,574,000	3,421,000	2,770,000	3,747,000	3,092,000
NA/HME [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	3,574,000	3,421,000	3,747,000	3,747,000	3,092,000	'
Restructuring Charges including Inventory Markdowns	644,000	1,948,000	1,679,000	'	4,242,000	4,755,000
Restructuring Reserve, Settled with Cash	-1,624,000	-1,795,000	-2,005,000	'	-3,587,000	-1,663,000
Restructuring Reserve, Ending Balance	2,594,000	3,574,000	3,421,000	2,594,000	3,747,000	3,092,000
NA/HME [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	0
Restructuring Reserve, Settled with Cash	0	0	0	'	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
NA/HME [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	213,000	0	0	'	5,000	0
Restructuring Reserve, Settled with Cash	-85,000	0	0	'	-5,000	0
Restructuring Reserve, Ending Balance	128,000	0	0	128,000	0	0
NA/HME [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	353,000	0	0	'	0	4,000
Restructuring Reserve, Settled with Cash	-305,000	0	0	'	0	-4,000
Restructuring Reserve, Ending Balance	48,000	0	0	48,000	0	0
IPG [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	159,000	172,000	0	0	71,000	'
Restructuring Charges including Inventory Markdowns	36,000	13,000	189,000	'	35,000	123,000
Restructuring Reserve, Settled with Cash	-52,000	-26,000	-17,000	'	-106,000	-52,000
Restructuring Reserve, Ending Balance	143,000	159,000	172,000	143,000	0	71,000
IPG [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	159,000	172,000	0	0	71,000	'
Restructuring Charges including Inventory Markdowns	36,000	13,000	189,000	'	35,000	123,000
Restructuring Reserve, Settled with Cash	-52,000	-26,000	-17,000	'	-106,000	-52,000
Restructuring Reserve, Ending Balance	143,000	159,000	172,000	143,000	0	71,000
IPG [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	0
Restructuring Reserve, Settled with Cash	0	0	0	'	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
IPG [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	0
Restructuring Reserve, Settled with Cash	0	0	0	'	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
IPG [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	0
Restructuring Reserve, Settled with Cash	0	0	0	'	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Europe [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	132,000	249,000	595,000	595,000	1,816,000	'
Restructuring Charges including Inventory Markdowns	541,000	65,000	115,000	'	2,093,000	5,466,000
Restructuring Reserve, Settled with Cash	41,000	-182,000	-461,000	'	-3,314,000	-3,650,000
Restructuring Reserve, Ending Balance	714,000	132,000	249,000	714,000	595,000	1,816,000
Europe [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	132,000	249,000	595,000	595,000	1,742,000	'
Restructuring Charges including Inventory Markdowns	739,000	65,000	115,000	'	817,000	3,288,000
Restructuring Reserve, Settled with Cash	-157,000	-182,000	-461,000	'	-1,964,000	-1,546,000
Restructuring Reserve, Ending Balance	714,000	132,000	249,000	714,000	595,000	1,742,000
Europe [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	277,000
Restructuring Reserve, Settled with Cash	0	0	0	'	0	-277,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Europe [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	74,000	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	53,000	1,788,000
Restructuring Reserve, Settled with Cash	0	0	0	'	-127,000	-1,714,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	74,000
Europe [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	-198,000	0	0	'	1,223,000	113,000
Restructuring Reserve, Settled with Cash	198,000	0	0	'	-1,223,000	-113,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Asia/Pacific [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	2,037,000	1,651,000	2,651,000	2,651,000	0	'
Restructuring Charges including Inventory Markdowns	97,000	566,000	539,000	'	5,020,000	186,000
Restructuring Reserve, Settled with Cash	-1,600,000	-180,000	-1,539,000	'	-2,369,000	-186,000
Restructuring Reserve, Ending Balance	534,000	2,037,000	1,651,000	534,000	2,651,000	0
Asia/Pacific [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	1,055,000	704,000	869,000	869,000	0	'
Restructuring Charges including Inventory Markdowns	15,000	480,000	453,000	'	1,681,000	186,000
Restructuring Reserve, Settled with Cash	-1,040,000	-129,000	-618,000	'	-812,000	-186,000
Restructuring Reserve, Ending Balance	30,000	1,055,000	704,000	30,000	869,000	0
Asia/Pacific [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	151,000	151,000	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	491,000	0
Restructuring Reserve, Settled with Cash	0	0	-151,000	'	-340,000	0
Restructuring Reserve, Ending Balance	0	0	0	0	151,000	0
Asia/Pacific [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	982,000	945,000	1,625,000	1,625,000	0	'
Restructuring Charges including Inventory Markdowns	79,000	86,000	86,000	'	1,667,000	0
Restructuring Reserve, Settled with Cash	-557,000	-49,000	-766,000	'	-42,000	0
Restructuring Reserve, Ending Balance	504,000	982,000	945,000	504,000	1,625,000	0
Asia/Pacific [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	2,000	6,000	6,000	0	'
Restructuring Charges including Inventory Markdowns	3,000	0	0	'	1,181,000	0
Restructuring Reserve, Settled with Cash	-3,000	-2,000	-4,000	'	-1,175,000	0
Restructuring Reserve, Ending Balance	$0	$0	$2,000	$0	$6,000	$0

Charges_Related_To_Restructuri3

Charges Related To Restructuring Activities Narrative (Details) (USD $)	3 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	$1,884,000	$2,592,000	$2,522,000	$6,998,000	$11,395,000	$10,534,000
Restructuring Reserve, Settled with Cash	3,625,000	2,183,000	4,022,000	9,830,000	9,381,000	5,555,000
Restructuring and Related Activities, Expected Payout Period	'	'	'	'12 months	'	'
Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	1,434,000	2,506,000	2,436,000	'	6,775,000	8,352,000
Restructuring Reserve, Settled with Cash	2,873,000	2,132,000	3,101,000	'	6,469,000	3,447,000
Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	292,000	86,000	86,000	'	1,725,000	1,788,000
Restructuring Reserve, Settled with Cash	642,000	49,000	766,000	'	174,000	1,714,000
Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	491,000	277,000
Restructuring Reserve, Settled with Cash	0	0	151,000	'	340,000	277,000
Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	158,000	0	0	'	2,404,000	117,000
Restructuring Reserve, Settled with Cash	110,000	2,000	4,000	'	2,398,000	117,000
Europe [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	541,000	65,000	115,000	'	2,093,000	5,466,000
Restructuring Reserve, Settled with Cash	-41,000	182,000	461,000	'	3,314,000	3,650,000
Europe [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	739,000	65,000	115,000	'	817,000	3,288,000
Restructuring Reserve, Settled with Cash	157,000	182,000	461,000	'	1,964,000	1,546,000
Europe [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	53,000	1,788,000
Restructuring Reserve, Settled with Cash	0	0	0	'	127,000	1,714,000
Europe [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	277,000
Restructuring Reserve, Settled with Cash	0	0	0	'	0	277,000
Europe [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	-198,000	0	0	'	1,223,000	113,000
Restructuring Reserve, Settled with Cash	-198,000	0	0	'	1,223,000	113,000
Asia Pacific [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	97,000	566,000	539,000	'	5,020,000	186,000
Restructuring Reserve, Settled with Cash	1,600,000	180,000	1,539,000	'	2,369,000	186,000
Asia Pacific [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	15,000	480,000	453,000	'	1,681,000	186,000
Restructuring Reserve, Settled with Cash	1,040,000	129,000	618,000	'	812,000	186,000
Asia Pacific [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	79,000	86,000	86,000	'	1,667,000	0
Restructuring Reserve, Settled with Cash	557,000	49,000	766,000	'	42,000	0
Asia Pacific [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	491,000	0
Restructuring Reserve, Settled with Cash	0	0	151,000	'	340,000	0
Asia Pacific [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	3,000	0	0	'	1,181,000	0
Restructuring Reserve, Settled with Cash	3,000	2,000	4,000	'	1,175,000	0
NA/HME [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	1,210,000	1,948,000	1,679,000	'	4,247,000	4,759,000
Restructuring Reserve, Settled with Cash	2,014,000	1,795,000	2,005,000	'	3,592,000	1,667,000
NA/HME [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	644,000	1,948,000	1,679,000	'	4,242,000	4,755,000
Restructuring Reserve, Settled with Cash	1,624,000	1,795,000	2,005,000	'	3,587,000	1,663,000
NA/HME [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	213,000	0	0	'	5,000	0
Restructuring Reserve, Settled with Cash	85,000	0	0	'	5,000	0
NA/HME [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	'	0	0
Restructuring Reserve, Settled with Cash	0	0	0	'	0	0
NA/HME [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	353,000	0	0	'	0	4,000
Restructuring Reserve, Settled with Cash	$305,000	$0	$0	'	$0	$4,000

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'
Effective Income Tax Rate, Continuing Operations	16.20%	81.30%	12.30%	97.50%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	'	'	35.00%	35.00%
Liability for Uncertain Tax Positions, Noncurrent	$3,143,000	$9,173,000	$3,143,000	$9,173,000
Income Tax Examination, Foreign Tax Expense (Benefit), Per Share	'	'	'	$0.29
Income Tax Examination, Penalties and Interest Accrued	'	$3,178,000	'	$3,178,000

Net_Earnings_Loss_Per_Common_S2

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Basic	'	'	'	'
Average common shares outstanding	31,902	31,877	31,902	31,838
Net Earnings (loss)	$16,102	$2,864	$38,821	$9,120
Net earnings (loss) per common share	$0.50	$0.09	$1.21	$0.28
Income (Loss) from Continuing Operations Attributable to Parent	-5,383	563	-35,580	374
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	21,485	2,301	74,401	8,746
Income (Loss) from Continuing Operations, Per Basic Share	($0.17)	$0.02	($1.12)	$0.01
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	$0.67	$0.07	$2.33	$0.27
Diluted	'	'	'	'
Average common shares outstanding	31,902	31,877	31,902	31,838
Shares related to convertible debt	0	0	0	0
Stock options and awards	164	24	107	9
Average common shares assuming dilution	32,066	31,901	32,009	31,847
Net Earnings (loss)	$16,102	$2,864	$38,821	$9,120
Net Earnings (loss) per Share - Assuming Dilution	$0.50	$0.09	$1.20	$0.28
Income (Loss) from Continuing Operations, Per Diluted Share	($0.17)	$0.02	($1.12)	$0.01
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	$0.67	$0.07	$2.32	$0.27

Net_Earnings_Loss_Per_Common_S3

Net Earnings (Loss) Per Common Share Textuals (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	4,375,829	4,639,809	4,406,045	4,679,093
Antidilutive Share Granted, Average Exercise Price	$41.87	$41.87	$41.87	$41.87
Fair value stock price	$15.88	$14.74	$15.04	$15.55

Concentration_Of_Credit_Risk_D

Concentration Of Credit Risk (Details) (USD $)	Sep. 30, 2013
Concentration Risk [Line Items]	'
Retained Recourse Obligation For Events Of Default Under Contracts	$7,074,000
Events of Default Under Contract by Third Party	$50,570,000

Derivatives_Notional_Amounts_D

Derivatives Notional Amounts (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Minimum [Member]

Maximum [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / CAD [Member]

EUR / CAD [Member]

EUR / DKK [Member]

EUR / DKK [Member]

AUD / EUR [Member]

AUD / EUR [Member]

AUD / GBP [Member]

AUD / GBP [Member]

AUD / CAD [Member]

AUD / CAD [Member]

EUR / NZD [Member]

EUR / NZD [Member]

AUD / NZD [Member]

AUD / NZD [Member]

EUR / NOK [Member]

EUR / NOK [Member]

DKK / SEK [Member]

DKK / SEK [Member]

EUR / CAD [Member]

EUR / CAD [Member]

EUR / CHF [Member]

EUR / CHF [Member]

EUR / GBP [Member]

EUR / GBP [Member]

EUR / SEK [Member]

EUR / SEK [Member]

EUR / NZD [Member]

EUR / NZD [Member]

GBP / CHF [Member]

GBP / CHF [Member]

GBP / SEK [Member]

GBP / SEK [Member]

NOK / CHF [Member]

NOK / CHF [Member]

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Percentage of Forcasted Transactions With Currency Rate Exposure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

90.00%

Notional Amount of Derivatives, Matured During Period

$51,251,000

$50,244,000

$131,923,000

$134,402,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount

'

'

'

'

53,104,000

23,782,000

0

1,908,000

0

239,000

0

-11,203,000

1,788,000

0

298,000

0

4,840,000

14,801,000

12,273,000

9,906,000

6,361,000

0

4,486,000

0

2,161,000

3,146,000

878,000

3,056,000

0

90,000

0

785,000

13,517,000

0

0

1,048,000

0

6,000

6,502,000

0

49,333,000

108,408,000

1,051,000

6,397,000

579,000

0

10,330,000

17,620,000

3,320,000

0

232,000

0

14,433,000

59,510,000

692,000

2,519,000

465,000

0

3,499,000

0

2,846,000

6,954,000

450,000

0

1,555,000

0

5,389,000

2,077,000

415,000

0

1,748,000

5,749,000

304,000

0

1,099,000

4,154,000

926,000

3,428,000

'

'

Unrealized Gain (Loss)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-55,000

-540,000

-9,000

-47,000

46,000

0

-85,000

-6,000

55,000

0

7,000

0

-368,000

-797,000

22,000

-3,000

4,000

0

115,000

0

11,000

141,000

12,000

0

17,000

0

-40,000

46,000

25,000

0

23,000

105,000

-8,000

0

52,000

25,000

66,000

-4,000

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives

$361,000

$569,000

$617,000

$551,000

$617,000

$551,000

$0

$5,000

$0

($15,000)

$0

($27,000)

$248,000

$0

$38,000

$0

$4,000

$434,000

$166,000

$134,000

$67,000

$0

$12,000

$0

($8,000)

$40,000

($4,000)

($38,000)

$0

($10,000)

$0

$13,000

$62,000

$0

$0

$15,000

$0

$0

$32,000

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivatives_Balance_Sheet_Loca

Derivatives Balance Sheet Location (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount of Derivatives, Matured During Period

'

'

$51,251,000

$50,244,000

$131,923,000

$134,402,000

'

'

'

'

'

'

Derivative Assets

1,311,000

1,062,000

'

'

'

'

626,000

375,000

685,000

687,000

0

0

Liabilities

$771,000

$1,373,000

'

'

'

'

$681,000

$915,000

$68,000

$142,000

$22,000

$316,000

Derivatives_Gain_Loss_in_State

Derivatives Gain (Loss) in Statement of Finacial Position (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2011

Sep. 30, 2013

Sep. 30, 2011

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / NOK [Member]

EUR / NOK [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Derivative Instruments, Gain (Loss) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)

($174,000)

($2,525,000)

$938,000

($3,055,000)

'

'

'

'

'

'

'

'

'

'

'

'

($207,000)

($2,522,000)

$505,000

($2,956,000)

'

'

'

'

$33,000

($3,000)

$433,000

($99,000)

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)

70,000

1,241,000

-159,000

2,706,000

'

'

'

'

'

'

'

'

'

'

'

'

83,000

1,241,000

-20,000

2,706,000

'

'

'

'

-13,000

0

-139,000

0

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Gain (Loss) Recognized in Income

'

'

'

'

54,000

-146,000

496,000

49,000

'

1,487,000

'

2,804,000

'

'

'

'

'

'

'

'

361,000

'

617,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)

2,000

-38,000

37,000

-9,000

'

'

'

'

'

'

'

'

'

'

'

'

2,000

-38,000

37,000

-9,000

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives

-74,000

1,341,000

43,000

2,853,000

'

'

'

'

'

'

'

'

361,000

569,000

617,000

551,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

617,000

551,000

0

5,000

0

0

Derivative Instruments, Gain (Loss) Recognized in Income

'

'

'

'

'

'

'

'

($128,000)

'

($453,000)

'

'

'

'

'

'

'

'

'

'

$569,000

'

$551,000

'

'

'

'

($23,000)

($147,000)

($328,000)

($419,000)

'

'

'

'

'

'

Fair_Values_of_Financial_Instr1

Fair Values of Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	$562	$5
Interest Rate Derivative Liabilities, at Fair Value	-22	-316
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	562	5
Interest Rate Derivative Liabilities, at Fair Value	-22	-316
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	$0	$0

Fair_Values_of_Financial_Instr2

Fair Values of Financial Instruments Details of Book Value and Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$32,625	$38,791	$35,282	$34,924
Installment receivables, net	1,560	2,188	'	'
Other current assets	33,830	41,776	'	'
Cash and Cash Equivalents [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	32,625	38,791	'	'
Cash and Cash Equivalents [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents	32,625	38,791	'	'
Other Assets [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	1,190	1,171	'	'
Other Assets [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	1,190	1,171	'	'
Accounts and Notes Receivable, Net [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	2,236	2,594	'	'
Accounts and Notes Receivable, Net [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	2,236	2,594	'	'
Debt [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-56,069	-234,802	'	'
Debt [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-56,115	-234,072	'	'
Foreign Exchange Forward [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	1,311	1,062	'	'
Accrued Expenses	-749	-1,057	'	'
Foreign Exchange Forward [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	1,311	1,062	'	'
Accrued Expenses	-749	-1,057	'	'
Interest Rate Swap [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	-22	-316	'	'
Interest Rate Swap [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	($22)	($316)	'	'

Business_Segments_Information_

Business Segments (Information by Segment) (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

$1,884,000

$2,592,000

$2,522,000

'

$6,998,000

'

$11,395,000

$10,534,000

'

Revenue from external customers

341,176,000

'

'

361,518,000

1,017,373,000

1,077,767,000

'

'

'

Intersegment revenues

30,056,000

'

'

37,730,000

89,551,000

123,081,000

'

'

'

Restructuring Charges

1,884,000

'

'

1,175,000

6,998,000

3,742,000

'

'

'

Earnings (loss) before income taxes

-4,633,000

'

'

3,008,000

-31,680,000

14,860,000

'

'

'

Restructuring Reserve, Settled with Cash

-3,625,000

-2,183,000

-4,022,000

'

-9,830,000

'

-9,381,000

-5,555,000

'

Restructuring Reserve

4,161,000

5,902,000

5,493,000

'

4,161,000

'

6,993,000

4,979,000

0

North America/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

151,052,000

'

'

170,701,000

462,261,000

527,103,000

'

'

'

Intersegment revenues

20,501,000

'

'

24,813,000

59,735,000

81,985,000

'

'

'

Restructuring Charges

1,210,000

'

'

352,000

4,837,000

2,214,000

'

'

'

Earnings (loss) before income taxes

-10,191,000

'

'

-28,000

-33,593,000

8,086,000

'

'

'

Institutional Products Group [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

28,083,000

'

'

33,557,000

87,135,000

95,726,000

'

'

'

Intersegment revenues

1,254,000

'

'

1,941,000

4,243,000

5,471,000

'

'

'

Restructuring Charges

36,000

'

'

0

237,000

35,000

'

'

'

Earnings (loss) before income taxes

1,009,000

'

'

579,000

1,955,000

4,820,000

'

'

'

Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

541,000

65,000

115,000

'

'

'

2,093,000

5,466,000

'

Revenue from external customers

150,265,000

'

'

141,705,000

429,650,000

401,721,000

'

'

'

Intersegment revenues

1,890,000

'

'

3,239,000

6,156,000

8,448,000

'

'

'

Restructuring Charges

542,000

'

'

481,000

722,000

772,000

'

'

'

Earnings (loss) before income taxes

13,136,000

'

'

10,218,000

27,344,000

23,504,000

'

'

'

Restructuring Reserve, Settled with Cash

41,000

-182,000

-461,000

'

'

'

-3,314,000

-3,650,000

'

Restructuring Reserve

714,000

132,000

249,000

'

714,000

'

595,000

1,816,000

'

Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

97,000

566,000

539,000

'

'

'

5,020,000

186,000

'

Revenue from external customers

11,776,000

'

'

15,555,000

38,327,000

53,217,000

'

'

'

Intersegment revenues

6,411,000

'

'

7,737,000

19,417,000

27,177,000

'

'

'

Restructuring Charges

96,000

'

'

342,000

1,202,000

721,000

'

'

'

Earnings (loss) before income taxes

-2,233,000

'

'

-2,301,000

-9,871,000

-4,139,000

'

'

'

Restructuring Reserve, Settled with Cash

-1,600,000

-180,000

-1,539,000

'

'

'

-2,369,000

-186,000

'

Restructuring Reserve

534,000

2,037,000

1,651,000

'

534,000

'

2,651,000

0

'

All Other Segments [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Earnings (loss) before income taxes

-6,354,000

[1]

'

'

-5,460,000

[1]

-17,515,000

[1]

-17,411,000

[1]

'

'

'

NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

1,210,000

1,948,000

1,679,000

'

'

'

4,247,000

4,759,000

'

Restructuring Reserve, Settled with Cash

-2,014,000

-1,795,000

-2,005,000

'

'

'

-3,592,000

-1,667,000

'

Restructuring Reserve

2,770,000

3,574,000

3,421,000

'

2,770,000

'

3,747,000

3,092,000

'

IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

36,000

13,000

189,000

'

'

'

35,000

123,000

'

Restructuring Reserve, Settled with Cash

-52,000

-26,000

-17,000

'

'

'

-106,000

-52,000

'

Restructuring Reserve

143,000

159,000

172,000

'

143,000

'

0

71,000

'

Severance [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

1,434,000

2,506,000

2,436,000

'

'

'

6,775,000

8,352,000

'

Restructuring Reserve, Settled with Cash

-2,873,000

-2,132,000

-3,101,000

'

'

'

-6,469,000

-3,447,000

'

Restructuring Reserve

3,481,000

4,920,000

4,546,000

'

3,481,000

'

5,211,000

4,905,000

0

Severance [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

739,000

65,000

115,000

'

'

'

817,000

3,288,000

'

Restructuring Reserve, Settled with Cash

-157,000

-182,000

-461,000

'

'

'

-1,964,000

-1,546,000

'

Restructuring Reserve

714,000

132,000

249,000

'

714,000

'

595,000

1,742,000

'

Severance [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

15,000

480,000

453,000

'

'

'

1,681,000

186,000

'

Restructuring Reserve, Settled with Cash

-1,040,000

-129,000

-618,000

'

'

'

-812,000

-186,000

'

Restructuring Reserve

30,000

1,055,000

704,000

'

30,000

'

869,000

0

'

Severance [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

644,000

1,948,000

1,679,000

'

'

'

4,242,000

4,755,000

'

Restructuring Reserve, Settled with Cash

-1,624,000

-1,795,000

-2,005,000

'

'

'

-3,587,000

-1,663,000

'

Restructuring Reserve

2,594,000

3,574,000

3,421,000

'

2,594,000

'

3,747,000

3,092,000

'

Severance [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

36,000

13,000

189,000

'

'

'

35,000

123,000

'

Restructuring Reserve, Settled with Cash

-52,000

-26,000

-17,000

'

'

'

-106,000

-52,000

'

Restructuring Reserve

143,000

159,000

172,000

'

143,000

'

0

71,000

'

Product Line Discontinuance [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

491,000

277,000

'

Restructuring Reserve, Settled with Cash

0

0

-151,000

'

'

'

-340,000

-277,000

'

Restructuring Reserve

0

0

0

'

0

'

151,000

0

0

Product Line Discontinuance [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

0

277,000

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

0

-277,000

'

Restructuring Reserve

0

0

0

'

0

'

0

0

'

Product Line Discontinuance [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

491,000

0

'

Restructuring Reserve, Settled with Cash

0

0

-151,000

'

'

'

-340,000

0

'

Restructuring Reserve

0

0

0

'

0

'

151,000

0

'

Product Line Discontinuance [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

0

0

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

0

0

'

Restructuring Reserve

0

0

0

'

0

'

0

0

'

Product Line Discontinuance [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

0

0

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

0

0

'

Restructuring Reserve

0

0

0

'

0

'

0

0

'

Contract Termination [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

292,000

86,000

86,000

'

'

'

1,725,000

1,788,000

'

Restructuring Reserve, Settled with Cash

-642,000

-49,000

-766,000

'

'

'

-174,000

-1,714,000

'

Restructuring Reserve

632,000

982,000

945,000

'

632,000

'

1,625,000

74,000

0

Contract Termination [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

53,000

1,788,000

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

-127,000

-1,714,000

'

Restructuring Reserve

0

0

0

'

0

'

0

74,000

'

Contract Termination [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

79,000

86,000

86,000

'

'

'

1,667,000

0

'

Restructuring Reserve, Settled with Cash

-557,000

-49,000

-766,000

'

'

'

-42,000

0

'

Restructuring Reserve

504,000

982,000

945,000

'

504,000

'

1,625,000

0

'

Contract Termination [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

213,000

0

0

'

'

'

5,000

0

'

Restructuring Reserve, Settled with Cash

-85,000

0

0

'

'

'

-5,000

0

'

Restructuring Reserve

128,000

0

0

'

128,000

'

0

0

'

Contract Termination [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

0

0

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

0

0

'

Restructuring Reserve

0

0

0

'

0

'

0

0

'

Other [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

158,000

0

0

'

'

'

2,404,000

117,000

'

Restructuring Reserve, Settled with Cash

-110,000

-2,000

-4,000

'

'

'

-2,398,000

-117,000

'

Restructuring Reserve

48,000

0

2,000

'

48,000

'

6,000

0

0

Other [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

-198,000

0

0

'

'

'

1,223,000

113,000

'

Restructuring Reserve, Settled with Cash

198,000

0

0

'

'

'

-1,223,000

-113,000

'

Restructuring Reserve

0

0

0

'

0

'

0

0

'

Other [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

3,000

0

0

'

'

'

1,181,000

0

'

Restructuring Reserve, Settled with Cash

-3,000

-2,000

-4,000

'

'

'

-1,175,000

0

'

Restructuring Reserve

0

0

2,000

'

0

'

6,000

0

'

Other [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

353,000

0

0

'

'

'

0

4,000

'

Restructuring Reserve, Settled with Cash

-305,000

0

0

'

'

'

0

-4,000

'

Restructuring Reserve

48,000

0

0

'

48,000

'

0

0

'

Other [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges including Inventory Markdowns

0

0

0

'

'

'

0

0

'

Restructuring Reserve, Settled with Cash

0

0

0

'

'

'

0

0

'

Restructuring Reserve

$0

$0

$0

'

$0

'

$0

$0

'

[1]

Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the bAll Otherb earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees.

Contingencies_Contingencies_De

Contingencies Contingencies (Details) (USD $)	0 Months Ended
	Dec. 21, 2012	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Consent Decree Court Approval Date	21-Dec-12	'
Loss Contingency Accrual, at Carrying Value	'	$3,800,000

Supplemental_Guarantor_Informa2

Supplemental Guarantor Information Consolidating Condensed Statements of Operations (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Feb. 17, 2007
					The Company (Parent) [Member]	The Company (Parent) [Member]	The Company (Parent) [Member]	The Company (Parent) [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Eliminations [Member]	Eliminations [Member]	Eliminations [Member]	Eliminations [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]
																					Convertible Subordinated Debt [Member]	Convertible Subordinated Debt [Member]
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net sales	$341,176,000	$361,518,000	$1,017,373,000	$1,077,767,000	$60,641,000	$90,406,000	$186,453,000	$275,742,000	$119,548,000	$116,339,000	$364,005,000	$355,378,000	$184,299,000	$183,801,000	$535,805,000	$540,535,000	($23,312,000)	($29,028,000)	($68,890,000)	($93,888,000)	'	'
Interest Rate	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	4.13%	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	135,000,000
Cost of Goods Sold	244,352,000	252,106,000	733,408,000	746,369,000	52,454,000	70,600,000	159,884,000	211,115,000	86,978,000	83,685,000	264,501,000	256,854,000	128,232,000	126,852,000	378,287,000	371,855,000	-23,312,000	-29,031,000	-69,264,000	-93,455,000	'	'
Gross Profit	96,824,000	109,412,000	283,965,000	331,398,000	8,187,000	19,806,000	26,569,000	64,627,000	32,570,000	32,654,000	99,504,000	98,524,000	56,067,000	56,949,000	157,518,000	168,680,000	0	3,000	374,000	-433,000	'	'
Selling, general and administrative expense	98,719,000	103,281,000	306,042,000	306,755,000	29,046,000	33,712,000	99,338,000	99,736,000	25,363,000	20,356,000	72,370,000	64,452,000	44,310,000	45,492,000	131,640,000	138,207,000	0	3,721,000	2,694,000	4,360,000	'	'
Restructuring Charges	1,884,000	1,175,000	6,998,000	3,742,000	1,597,000	334,000	5,078,000	2,085,000	36,000	18,000	49,000	39,000	251,000	823,000	1,871,000	1,618,000	0	0	0	0	'	'
Loss on debt extinguishment including debt finance charges and associated fees	0	0	0	312,000	'	0	'	312,000	'	0	'	0	'	0	'	0	'	0	'	0	'	'
Asset Impairment Charges	167,000	0	167,000	0	0	'	0	'	167,000	'	'	'	0	'	0	'	0	'	0	'	'	'
Payment of Financing Costs	'	'	0	-1,000	'	'	'	-1,000	'	'	'	0	'	'	'	0	'	'	'	0	'	'
Income (Loss) from Equity Method Investments	0	0	0	0	32,513,000	17,302,000	105,501,000	45,175,000	8,935,000	-4,264,000	21,472,000	1,954,000	22,000	228,000	-93,000	391,000	-41,470,000	-13,266,000	-126,880,000	-47,520,000	'	'
Interest Income (Expense), Net	687,000	1,948,000	2,438,000	5,729,000	-603,000	-1,024,000	-1,418,000	-3,041,000	1,213,000	2,201,000	3,141,000	6,396,000	77,000	771,000	715,000	2,374,000	0	0	0	0	'	'
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	-4,633,000	3,008,000	-31,680,000	14,860,000	10,660,000	4,086,000	29,072,000	10,710,000	14,726,000	5,815,000	45,249,000	29,591,000	11,451,000	10,091,000	23,199,000	26,872,000	-41,470,000	-16,984,000	-129,200,000	-52,313,000	'	'
Income Tax Expense (Benefit)	750,000	2,445,000	3,900,000	14,486,000	-5,442,000	1,222,000	-9,749,000	1,590,000	0	-3,028,000	0	-5,164,000	6,192,000	4,251,000	13,649,000	18,060,000	0	0	0	0	'	'
Income (Loss) from Continuing Operations Attributable to Parent	-5,383,000	563,000	-35,580,000	374,000	16,102,000	2,864,000	38,821,000	9,120,000	14,726,000	8,843,000	45,249,000	34,755,000	5,259,000	5,840,000	9,550,000	8,812,000	-41,470,000	-16,984,000	-129,200,000	-52,313,000	'	'
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	21,485,000	2,301,000	74,401,000	8,746,000	0	0	0	0	21,485,000	2,301,000	74,401,000	8,746,000	0	0	0	0	0	0	0	0	'	'
Net Earnings (loss)	16,102,000	2,864,000	38,821,000	9,120,000	16,102,000	2,864,000	38,821,000	9,120,000	36,211,000	11,144,000	119,650,000	43,501,000	5,259,000	5,840,000	9,550,000	8,812,000	-41,470,000	-16,984,000	-129,200,000	-52,313,000	'	'
Other Comprehensive Income (Loss), Net of Tax	9,874,000	14,518,000	1,845,000	-24,673,000	9,874,000	14,518,000	1,845,000	-24,673,000	220,000	3,164,000	-415,000	3,179,000	10,135,000	11,412,000	2,228,000	-27,878,000	-10,355,000	-14,576,000	-1,813,000	24,699,000	'	'
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$25,976,000	$17,382,000	$40,666,000	($15,553,000)	$25,976,000	$17,382,000	$40,666,000	($15,553,000)	$36,431,000	$14,308,000	$119,235,000	$46,680,000	$15,394,000	$17,252,000	$11,778,000	($19,066,000)	($51,825,000)	($31,560,000)	($131,013,000)	($27,614,000)	'	'

Supplemental_Guarantor_Informa3

Supplemental Guarantor Information Consolidating Condensed Balance Sheets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current Assets	'	'	'	'
Cash and cash equivalents	$32,625	$38,791	$35,282	$34,924
Trade receivables, net	191,464	198,791	'	'
Installment receivables, net	1,560	2,188	'	'
Inventories, net	167,368	183,246	'	'
Due from Affiliate, Current	0	0	'	'
Other current assets	33,830	41,776	'	'
Assets Held-for-sale, Current	0	103,157	'	'
Total Current Assets	426,847	567,949	'	'
Investment in subsidiaries	0	0	'	'
Intercompany advances, net	0	0	'	'
Other Assets	40,327	42,262	'	'
Other Intangibles	65,105	71,652	'	'
Property and Equipment, net	108,391	118,231	'	'
Goodwill	450,727	462,200	'	'
Total Assets	1,091,397	1,262,294	'	'
Current Liabilities	'	'	'	'
Accounts payable	117,684	133,048	'	'
Accrued expenses	130,479	135,189	'	'
Accrued income taxes	7,201	2,713	'	'
Due to Affiliate, Current	0	0	'	'
Short-term debt and current maturities of long-term obligations	1,294	5,427	'	'
Liabilities of Assets Held-for-sale	0	23,358	'	'
Total Current Liabilities	256,658	299,735	'	'
Long-Term Debt	54,775	229,375	'	'
Other Long-Term Obligations	114,773	112,195	'	'
Inercompany advances, net	0	0	'	'
Total Shareholders' Equity	665,191	620,989	'	'
Total Liabilities and Shareholders' Equity	1,091,397	1,262,294	'	'
The Company (Parent) [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	3,148	5,774	5,419	3,642
Trade receivables, net	69,633	71,622	'	'
Installment receivables, net	0	0	'	'
Inventories, net	37,797	40,278	'	'
Due from Affiliate, Current	5,055	4,077	'	'
Other current assets	6,371	12,727	'	'
Assets Held-for-sale, Current	'	0	'	'
Total Current Assets	122,004	134,478	'	'
Investment in subsidiaries	1,433,252	1,536,898	'	'
Intercompany advances, net	937,116	863,973	'	'
Other Assets	38,961	41,006	'	'
Other Intangibles	553	663	'	'
Property and Equipment, net	36,783	39,911	'	'
Goodwill	0	0	'	'
Total Assets	2,568,669	2,616,929	'	'
Current Liabilities	'	'	'	'
Accounts payable	50,462	63,812	'	'
Accrued expenses	30,864	36,716	'	'
Accrued income taxes	5,540	1,545	'	'
Due to Affiliate, Current	41,889	61,368	'	'
Short-term debt and current maturities of long-term obligations	556	4,552	'	'
Liabilities of Assets Held-for-sale	'	0	'	'
Total Current Liabilities	129,311	167,993	'	'
Long-Term Debt	22,476	223,014	'	'
Other Long-Term Obligations	54,176	52,957	'	'
Inercompany advances, net	1,707,515	1,551,976	'	'
Total Shareholders' Equity	655,191	620,989	'	'
Total Liabilities and Shareholders' Equity	2,568,669	2,616,929	'	'
Combined Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	0	1,018	2,665	2,104
Trade receivables, net	29,453	37,223	'	'
Installment receivables, net	569	829	'	'
Inventories, net	27,784	31,455	'	'
Due from Affiliate, Current	664	763	'	'
Other current assets	570	473	'	'
Assets Held-for-sale, Current	'	103,157	'	'
Total Current Assets	59,040	174,918	'	'
Investment in subsidiaries	440,197	523,176	'	'
Intercompany advances, net	1,592,785	1,468,405	'	'
Other Assets	463	314	'	'
Other Intangibles	19,139	22,211	'	'
Property and Equipment, net	18,621	19,957	'	'
Goodwill	16,660	32,937	'	'
Total Assets	2,146,905	2,241,918	'	'
Current Liabilities	'	'	'	'
Accounts payable	8,237	9,465	'	'
Accrued expenses	17,737	18,155	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	1,481	2,369	'	'
Short-term debt and current maturities of long-term obligations	7	7	'	'
Liabilities of Assets Held-for-sale	'	23,358	'	'
Total Current Liabilities	27,462	53,354	'	'
Long-Term Debt	82	143	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	936,722	863,585	'	'
Total Shareholders' Equity	1,182,639	1,324,836	'	'
Total Liabilities and Shareholders' Equity	2,146,905	2,241,918	'	'
Combined Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	29,477	31,999	27,198	29,178
Trade receivables, net	92,378	89,946	'	'
Installment receivables, net	991	1,359	'	'
Inventories, net	104,970	114,169	'	'
Due from Affiliate, Current	43,145	64,570	'	'
Other current assets	34,129	34,606	'	'
Assets Held-for-sale, Current	'	0	'	'
Total Current Assets	305,090	336,649	'	'
Investment in subsidiaries	0	6,888	'	'
Intercompany advances, net	178,180	173,903	'	'
Other Assets	903	942	'	'
Other Intangibles	45,413	48,778	'	'
Property and Equipment, net	52,987	58,363	'	'
Goodwill	434,067	429,263	'	'
Total Assets	1,016,640	1,054,786	'	'
Current Liabilities	'	'	'	'
Accounts payable	58,985	59,771	'	'
Accrued expenses	89,118	86,348	'	'
Accrued income taxes	1,661	1,168	'	'
Due to Affiliate, Current	5,494	5,673	'	'
Short-term debt and current maturities of long-term obligations	731	868	'	'
Liabilities of Assets Held-for-sale	'	0	'	'
Total Current Liabilities	155,989	153,828	'	'
Long-Term Debt	32,217	6,218	'	'
Other Long-Term Obligations	60,597	59,238	'	'
Inercompany advances, net	63,844	90,720	'	'
Total Shareholders' Equity	703,993	744,782	'	'
Total Liabilities and Shareholders' Equity	1,016,640	1,054,786	'	'
Eliminations [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Trade receivables, net	0	0	'	'
Installment receivables, net	0	0	'	'
Inventories, net	-3,183	-2,656	'	'
Due from Affiliate, Current	-48,864	-69,410	'	'
Other current assets	-7,240	-6,030	'	'
Assets Held-for-sale, Current	'	0	'	'
Total Current Assets	-59,287	-78,096	'	'
Investment in subsidiaries	-1,873,449	-2,066,962	'	'
Intercompany advances, net	-2,708,081	-2,506,281	'	'
Other Assets	0	0	'	'
Other Intangibles	0	0	'	'
Property and Equipment, net	0	0	'	'
Goodwill	0	0	'	'
Total Assets	-4,640,817	-4,651,339	'	'
Current Liabilities	'	'	'	'
Accounts payable	0	0	'	'
Accrued expenses	-7,240	-6,030	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	-48,864	-69,410	'	'
Short-term debt and current maturities of long-term obligations	0	0	'	'
Liabilities of Assets Held-for-sale	'	0	'	'
Total Current Liabilities	-56,104	-75,440	'	'
Long-Term Debt	0	0	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	-2,708,081	-2,506,281	'	'
Total Shareholders' Equity	-1,876,632	-2,069,618	'	'
Total Liabilities and Shareholders' Equity	($4,640,817)	($4,651,339)	'	'

Supplemental_Guarantor_Informa4

Supplemental Guarantor Information Consolidating Condensed Statement of Cash Flows (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	($1,245)	$26,822
Investing Activities	'	'
Purchases of property and equipment	-11,086	-14,775
Proceeds from sale of property and equipment	856	97
Proceeds from Divestiture of Business, net	187,552	0
Other long-term assets	949	409
Other	-147	-219
Net Cash Used for Investing Activities	178,124	-14,488
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	250,124	255,703
Payments on revolving lines of credit and long-term borrowings	-432,185	-266,721
Payment of Financing Costs	0	-1
Payment of dividends	-1,187	-1,183
Net Cash Provided (Used) by Financing Activities	-183,248	-12,202
Effect of exchange rate changes on cash	203	226
Increase (decrease) in cash and cash equivalents	-6,166	358
Cash and cash equivalents at beginning of year	38,791	34,924
Cash and cash equivalents at end of year	32,625	35,282
The Company (Parent) [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	35,179	18,260
Investing Activities	'	'
Purchases of property and equipment	-3,234	-1,353
Proceeds from sale of property and equipment	0	18
Proceeds from Divestiture of Business, net	0	'
Other long-term assets	783	-214
Other	171,353	-158
Net Cash Used for Investing Activities	168,902	-1,707
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	226,189	252,590
Payments on revolving lines of credit and long-term borrowings	-431,709	-266,182
Payment of Financing Costs	'	-1
Payment of dividends	-1,187	-1,183
Net Cash Provided (Used) by Financing Activities	-206,707	-14,776
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	-2,626	1,777
Cash and cash equivalents at beginning of year	5,774	3,642
Cash and cash equivalents at end of year	3,148	5,419
Combined Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-81,077	5,405
Investing Activities	'	'
Purchases of property and equipment	-3,611	-7,854
Proceeds from sale of property and equipment	11	14
Other long-term assets	0	0
Other	-103,417	-117
Net Cash Used for Investing Activities	80,535	-7,957
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	3,113
Payments on revolving lines of credit and long-term borrowings	-476	0
Payment of Financing Costs	'	0
Payment of dividends	0	0
Net Cash Provided (Used) by Financing Activities	-476	3,113
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	-1,018	561
Cash and cash equivalents at beginning of year	1,018	2,104
Cash and cash equivalents at end of year	0	2,665
Combined Non-Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-20,736	7,527
Investing Activities	'	'
Purchases of property and equipment	-4,241	-5,568
Proceeds from sale of property and equipment	845	65
Proceeds from Divestiture of Business, net	0	'
Other long-term assets	166	623
Other	0	56
Net Cash Used for Investing Activities	-3,230	-4,824
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	23,935	0
Payments on revolving lines of credit and long-term borrowings	0	-539
Payment of Financing Costs	'	0
Payment of dividends	-2,694	-4,370
Net Cash Provided (Used) by Financing Activities	21,241	-4,909
Effect of exchange rate changes on cash	203	226
Increase (decrease) in cash and cash equivalents	-2,522	-1,980
Cash and cash equivalents at beginning of year	31,999	29,178
Cash and cash equivalents at end of year	29,477	27,198
Eliminations [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	65,389	-4,370
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	0	'
Other long-term assets	0	0
Other	-68,083	0
Net Cash Used for Investing Activities	-68,083	0
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	0
Payments on revolving lines of credit and long-term borrowings	0	0
Payment of Financing Costs	'	0
Payment of dividends	2,694	4,370
Net Cash Provided (Used) by Financing Activities	2,694	4,370
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of year	0	0
Cash and cash equivalents at end of year	$0	$0